

NK cells and cancer: you can teach innate cells new tricks

Nature Reviews Cancer

16, 7-19

DOI: [10.1038/nrc.2015.5](https://doi.org/10.1038/nrc.2015.5)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight, 2016, 1, e89829.	5.0	569
2	Metabolic Regulation of Natural Killer Cell IFN- γ Production. Critical Reviews in Immunology, 2016, 36, 131-147.	0.5	101
3	Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches. Frontiers in Immunology, 2016, 7, 152.	4.8	80
4	The Sweet Side of Immune Evasion: Role of Glycans in the Mechanisms of Cancer Progression. Frontiers in Oncology, 2016, 6, 54.	2.8	46
5	Zinc-Induced Polymerization of Killer-Cell Ig-like Receptor into Filaments Promotes Its Inhibitory Function at Cytotoxic Immunological Synapses. Molecular Cell, 2016, 62, 21-33.	9.7	23
6	Expanded and armed natural killer cells for cancer treatment. Cytotherapy, 2016, 18, 1422-1434.	0.7	63
7	Chimeric antigen receptor-engineered primary natural killer cells: a tool to improve adoptive tumor immunotherapy. Immunotherapy, 2016, 8, 983-986.	2.0	0
8	Novel therapeutic targets on the horizon for lung cancer. Lancet Oncology, The, 2016, 17, e347-e362.	10.7	156
9	Nanoparticles for cancer gene therapy: Recent advances, challenges, and strategies. Pharmacological Research, 2016, 114, 56-66.	7.1	110
10	TriKEs and BiKEs join CARs on the cancer immunotherapy highway. Human Vaccines and Immunotherapeutics, 2016, 12, 2790-2796.	3.3	47
11	NK cells and type 1 innate lymphoid cells: partners in host defense. Nature Immunology, 2016, 17, 758-764.	14.5	413
12	Involvement of autophagy in NK cell development and function. Autophagy, 2017, 13, 633-636.	9.1	27
13	Biallelic IRF8 Mutations Causing NK Cell Deficiency. Trends in Molecular Medicine, 2017, 23, 195-197.	6.7	2
14	Enhancement of NK cell-mediated lysis of non-small lung cancer cells by nPKC activator, ingenol 3,20 dibenzoate. Molecular Immunology, 2017, 83, 23-32.	2.2	9
15	Radiotherapy and immunotherapy: a beneficial liaison?. Nature Reviews Clinical Oncology, 2017, 14, 365-379.	27.6	760
16	The Activating Human NK Cell Receptor KIR2DS2 Recognizes a β 2-Microglobulin-Independent Ligand on Cancer Cells. Journal of Immunology, 2017, 198, 2556-2567.	0.8	35
18	Standardized and flexible eight colour flow cytometry panels harmonized between different laboratories to study human NK cell phenotype and function. Scientific Reports, 2017, 7, 43873.	3.3	28
19	Designing nanomedicine for immuno-oncology. Nature Biomedical Engineering, 2017, 1, .	22.5	178

#	ARTICLE	IF	CITATIONS
20	Identifying the optimal anticancer targets from the landscape of a cancer-immunity interaction network. <i>Physical Chemistry Chemical Physics</i> , 2017, 19, 7642-7651.	2.8	22
21	Viewing Siglecs through the lens of tumor immunology. <i>Immunological Reviews</i> , 2017, 276, 178-191.	6.0	115
22	Identification of New Lead Molecules Against UBE2NL Enzyme for Cancer Therapy. <i>Applied Biochemistry and Biotechnology</i> , 2017, 182, 1497-1517.	2.9	11
24	Leveraging natural killer cells for cancer immunotherapy. <i>Immunotherapy</i> , 2017, 9, 487-497.	2.0	26
25	Plastic Heterogeneity of Innate Lymphoid Cells in Cancer. <i>Trends in Cancer</i> , 2017, 3, 326-335.	7.4	23
26	Saliva exosomes from pancreatic tumor-bearing mice modulate NK cell phenotype and antitumor cytotoxicity. <i>FASEB Journal</i> , 2017, 31, 998-1010.	0.5	57
27	Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival. <i>Modern Pathology</i> , 2017, 30, 1287-1298.	5.5	23
28	Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV. <i>Protein and Cell</i> , 2017, 8, 861-877.	11.0	53
29	Overview: NK-cell-based Immunotherapies: Toward & Into Clinical Trials. <i>Clinical Immunology</i> , 2017, 177, 1-2.	3.2	2
30	Evolving adoptive cellular therapies in urological malignancies. <i>Lancet Oncology</i> , The, 2017, 18, e341-e353.	10.7	22
31	Lenalidomide acts as an adjuvant for HCV DNA vaccine. <i>International Immunopharmacology</i> , 2017, 48, 231-240.	3.8	9
32	Molecular checkpoints controlling natural killer cell activation and their modulation for cancer immunotherapy. <i>Experimental and Molecular Medicine</i> , 2017, 49, e311-e311.	7.7	36
33	The histone deacetylase inhibitor valproic acid inhibits NKG2D expression in natural killer cells through suppression of STAT3 and HDAC3. <i>Scientific Reports</i> , 2017, 7, 45266.	3.3	61
34	Antimetastatic effect of glycoprotein isolated from rice bran on colon 26-M3.1 cell line. <i>Journal of Functional Foods</i> , 2017, 32, 278-284.	3.4	8
35	IL-15 Enables Septic Shock by Maintaining NK Cell Integrity and Function. <i>Journal of Immunology</i> , 2017, 198, 1320-1333.	0.8	33
36	Patient-Derived Xenografts in Oncology. <i>Cancer Drug Discovery and Development</i> , 2017, , 13-40.	0.4	0
37	IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity. <i>Nature</i> , 2017, 551, 110-114.	27.8	176
39	Immune recognition of irradiated cancer cells. <i>Immunological Reviews</i> , 2017, 280, 220-230.	6.0	73

#	ARTICLE	IF	CITATIONS
40	NK Cells and $\gamma\delta$ T Cells for Relapse Protection after Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Current Stem Cell Reports</i> , 2017, 3, 301-311.	1.6	13
41	Stromal Expression of Activated Leukocyte Cell Adhesion Molecule Promotes Lung Tumor Growth and Metastasis. <i>American Journal of Pathology</i> , 2017, 187, 2558-2569.	3.8	12
42	Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. <i>Onc Immunology</i> , 2017, 6, e1371896.	4.6	36
43	Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy. <i>Seminars in Immunology</i> , 2017, 31, 64-75.	5.6	110
44	Intravascular Survival and Extravasation of Tumor Cells. <i>Cancer Cell</i> , 2017, 32, 282-293.	16.8	285
45	Tailoring Natural Killer cell immunotherapy to the tumour microenvironment. <i>Seminars in Immunology</i> , 2017, 31, 30-36.	5.6	30
46	Innate immune cells for immunotherapy of autoimmune and cancer disorders. <i>International Reviews of Immunology</i> , 2017, 36, 315-337.	3.3	16
47	Human cytomegalovirus escapes immune recognition by NK cells through the downregulation of B7-H6 by the viral genes US18 and US20. <i>Scientific Reports</i> , 2017, 7, 8661.	3.3	37
48	Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells. <i>Scientific Reports</i> , 2017, 7, 10445.	3.3	29
49	Advances in cancer stem cell targeting: How to strike the evil at its root. <i>Advanced Drug Delivery Reviews</i> , 2017, 120, 89-107.	13.7	58
50	Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. <i>Nature Immunology</i> , 2017, 18, 1004-1015.	14.5	504
51	Microfluidics Cell Loading&Dock System: Ordered Cellular Array for Dynamic Lymphocyte&Communication Study. <i>Advanced Biology</i> , 2017, 1, e1700085.	3.0	27
52	Control of Metastasis by NK Cells. <i>Cancer Cell</i> , 2017, 32, 135-154.	16.8	549
53	Myc Cooperates with Ras by Programming Inflammation and Immune Suppression. <i>Cell</i> , 2017, 171, 1301-1315.e14.	28.9	393
54	The IKK/NF- κ B signaling pathway requires Morgana to drive breast cancer metastasis. <i>Nature Communications</i> , 2017, 8, 1636.	12.8	73
55	CEACAM1 as a Multi-Purpose Target for Cancer Immunotherapy. <i>Onc Immunology</i> , 2017, 6, 00-00.	4.6	79
56	Dendritic Cell&Derived IL-32 \pm : A Novel Inhibitory Cytokine of NK Cell Function. <i>Journal of Immunology</i> , 2017, 199, 1290-1300.	0.8	21
57	Soluble NKG2D ligands limit the efficacy of immune checkpoint blockade. <i>Onc Immunology</i> , 2017, 6, e1346766.	4.6	21

#	ARTICLE	IF	CITATIONS
58	Uncovering the underlying mechanism of cancer tumorigenesis and development under an immune microenvironment from global quantification of the landscape. <i>Journal of the Royal Society Interface</i> , 2017, 14, 20170105.	3.4	28
59	PD-L1 and IAPs co-operate to protect tumors from cytotoxic lymphocyte-derived TNF. <i>Cell Death and Differentiation</i> , 2017, 24, 1705-1716.	11.2	64
60	Friend or Foe? The Ambiguous Role of Innate Lymphoid Cells in Cancer Development. <i>Trends in Immunology</i> , 2017, 38, 29-38.	6.8	47
61	Deciphering the killerâ€cell immunoglobulinâ€like receptor system at superâ€resolution for natural killer and Tâ€cell biology. <i>Immunology</i> , 2017, 150, 248-264.	4.4	74
62	Delivery of therapeutics with nanoparticles: what's new in cancer immunotherapy?. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2017, 9, e1421.	6.1	72
63	Immune and inflammatory responses to DNA damage in cancer and aging. <i>Mechanisms of Ageing and Development</i> , 2017, 165, 10-16.	4.6	32
64	Natural killer cell subsets and receptor expression in peripheral blood mononuclear cells of a healthy Korean population: Reference range, influence of age and sex, and correlation between NK cell receptors and cytotoxicity. <i>Human Immunology</i> , 2017, 78, 103-112.	2.4	41
65	Natural killer-cell deficiency alters placental development in ratsâ€. <i>Biology of Reproduction</i> , 2017, 96, 145-158.	2.7	41
66	The Effects of Artemisinin on the Cytolytic Activity of Natural Killer (NK) Cells. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1600.	4.1	25
67	Regulation of NK Cell Activation and Effector Functions by the IL-12 Family of Cytokines: The Case of IL-27. <i>Frontiers in Immunology</i> , 2017, 8, 25.	4.8	97
68	Type I Interferons and Natural Killer Cell Regulation in Cancer. <i>Frontiers in Immunology</i> , 2017, 8, 304.	4.8	113
69	A Two-Phase Expansion Protocol Combining Interleukin (IL)-15 and IL-21 Improves Natural Killer Cell Proliferation and Cytotoxicity against Rhabdomyosarcoma. <i>Frontiers in Immunology</i> , 2017, 8, 676.	4.8	70
70	Chronic NKG2D Engagement In Vivo Differentially Impacts NK Cell Responsiveness by Activating NK Receptors. <i>Frontiers in Immunology</i> , 2017, 8, 1466.	4.8	20
71	Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma. <i>Frontiers in Immunology</i> , 2017, 8, 1617.	4.8	43
72	The Unique Molecular and Cellular Microenvironment of Ovarian Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 24.	2.8	187
73	The Role of Microglia and Macrophages in CNS Homeostasis, Autoimmunity, and Cancer. <i>Journal of Immunology Research</i> , 2017, 2017, 1-12.	2.2	140
74	Circulating Tumor Cells Were Associated with the Number of T Lymphocyte Subsets and NK Cells in Peripheral Blood in Advanced Non-Small-Cell Lung Cancer. <i>Disease Markers</i> , 2017, 2017, 1-6.	1.3	39
75	Endothelial cells express NKG2D ligands and desensitize antitumor NK responses. <i>ELife</i> , 2017, 6, .	6.0	71

#	ARTICLE	IF	CITATIONS
76	NK Cells and Cancer. , 0, , .		1
77	NK Cells in Cancer Immunotherapy. , 0, , .		0
78	Nanoparticle Design Strategies for Effective Cancer Immunotherapy. Journal of Biomedicine (Sydney,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.4	48
79	Is folic acid safe for non-“muscle-invasive bladder cancer patients? An evidence-based cohort study. American Journal of Clinical Nutrition, 2018, 107, 208-216.	4.7	19
80	Early Reconstitution of NK and T Cells and Its Implication for the Design of Post-Transplant Immunotherapy. Biology of Blood and Marrow Transplantation, 2018, 24, 1152-1162.	2.0	56
81	Awakening exhausted NK cells in lymphomas. Blood, 2018, 131, 1768-1769.	1.4	2
82	Implication of Highly Cytotoxic Natural Killer Cells for Esophageal Squamous Cell Carcinoma Treatment. Journal of Immunotherapy, 2018, 41, 261-273.	2.4	12
83	Reducing the Cytotoxicity of Lipid Nanoparticles Associated with a Fusogenic Cationic Lipid in a Natural Killer Cell Line by Introducing a Polycation-Based siRNA Core. Molecular Pharmaceutics, 2018, 15, 2142-2150.	4.6	49
84	Re(de)fining Innate Lymphocyte Lineages in the Face of Cancer. Cancer Immunology Research, 2018, 6, 372-377.	3.4	10
85	Crk Adaptor Proteins Regulate NK Cell Expansion and Differentiation during Mouse Cytomegalovirus Infection. Journal of Immunology, 2018, 200, 3420-3428.	0.8	8
86	The tolerogenic role of IFN- γ . Cytokine and Growth Factor Reviews, 2018, 41, 40-53.	7.2	54
87	Antitumor Research on Artemisinin and Its Bioactive Derivatives. Natural Products and Bioprospecting, 2018, 8, 303-319.	4.3	66
88	Escaping NK cells and recruiting neutrophils: How Morgana/NF- κ B signaling promotes metastasis. Molecular and Cellular Oncology, 2018, 5, e1432258.	0.7	1
89	Immuno-oncology-101: overview of major concepts and translational perspectives. Seminars in Cancer Biology, 2018, 52, 1-11.	9.6	39
90	Current state and future prospects of immunotherapy for glioma. Immunotherapy, 2018, 10, 317-339.	2.0	60
91	New Job for NK Cells: Architects of the Tumor Microenvironment. Immunity, 2018, 48, 9-11.	14.3	21
92	Diversification of human NK cells: Lessons from deep profiling. Journal of Leukocyte Biology, 2018, 103, 629-641.	3.3	56
93	Tuning inflammation and immunity by the negative regulators IL-1R2 and IL-1R8 . Immunological Reviews, 2018, 281, 233-247.	6.0	73

#	ARTICLE	IF	CITATIONS
94	Is There Natural Killer Cell Memory and Can It Be Harnessed by Vaccination?. Cold Spring Harbor Perspectives in Biology, 2018, 10, a029488.	5.5	7
95	Is There Natural Killer Cell Memory and Can It Be Harnessed by Vaccination?. Cold Spring Harbor Perspectives in Biology, 2018, 10, a029538.	5.5	41
96	Chimeric Antigen Receptors in Different Cell Types: New Vehicles Join the Race. Human Gene Therapy, 2018, 29, 547-558.	2.7	29
97	NKp46 Receptor-Mediated Interferon- γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis. Immunity, 2018, 48, 107-119.e4.	14.3	143
98	Whole Blood Gene Expression Profiling in patients undergoing colon cancer surgery identifies differential expression of genes involved in immune surveillance, inflammation and carcinogenesis. Surgical Oncology, 2018, 27, 208-215.	1.6	10
99	Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Current Opinion in Immunology, 2018, 51, 146-153.	5.5	178
100	Tumor Ablation and Therapeutic Immunity Induction by an Injectable Peptide Hydrogel. ACS Nano, 2018, 12, 3295-3310.	14.6	143
101	A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab. Journal of Neurosurgery, 2018, 128, 1419-1427.	1.6	17
102	Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors. Oncoimmunology, 2018, 7, e1392426.	4.6	49
103	Chromatin organization as an indicator of glucocorticoid induced natural killer cell dysfunction. Brain, Behavior, and Immunity, 2018, 67, 279-289.	4.1	6
104	Concise Review: Human Pluripotent Stem Cells to Produce Cell-Based Cancer Immunotherapy. Stem Cells, 2018, 36, 134-145.	3.2	48
105	Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy. Biomedicine and Pharmacotherapy, 2018, 97, 225-232.	5.6	31
106	Harnessing innate lung anti-cancer effector functions with a novel bacterial-derived immunotherapy. Oncoimmunology, 2018, 7, e1398875.	4.6	16
108	Cellular Therapy. Current Cancer Research, 2018, , 133-184.	0.2	0
109	Genotyping Natural Killer Immune Checkpoints to Discover Biomarkers of Response. Clinical Cancer Research, 2018, 24, 3-5.	7.0	6
110	Tumor immunotherapy: New aspects of natural killer cells. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 173-196.	2.2	52
111	A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D;) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.8	110
112	Ginsenoside F1 Promotes Cytotoxic Activity of NK Cells via Insulin-Like Growth Factor-1-Dependent Mechanism. Frontiers in Immunology, 2018, 9, 2785.	4.8	19

#	ARTICLE	IF	CITATIONS
113	Inflammation: A key process in skin tumorigenesis (Review). <i>Oncology Letters</i> , 2018, 17, 4068-4084.	1.8	77
114	The Adaptive Complexity of Cancer. <i>BioMed Research International</i> , 2018, 2018, 1-14.	1.9	17
115	Cell-Membrane Immunotherapy Based on Natural Killer Cell Membrane Coated Nanoparticles for the Effective Inhibition of Primary and Abscopal Tumor Growth. <i>ACS Nano</i> , 2018, 12, 12096-12108.	14.6	285
116	Natural Killer Cell Dysfunction in Hepatocellular Carcinoma: Pathogenesis and Clinical Implications. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3648.	4.1	32
117	NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. <i>Science</i> , 2018, 362, 1416-1422.	12.6	267
118	Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells. , 2018, 6, 136.		108
119	A Single-Step Chemoenzymatic Reaction for the Construction of Antibody-Cell Conjugates. <i>ACS Central Science</i> , 2018, 4, 1633-1641.	11.3	59
120	Propofol (TIVA) Versus Volatile-Based Anesthetics: Is There Any Oncological Benefit?. <i>Current Anesthesiology Reports</i> , 2018, 8, 399-410.	2.0	1
121	A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing. <i>Cancer Immunology Research</i> , 2018, 6, 1511-1523.	3.4	59
122	When and how NK cell-induced programmed cell death benefits immunological protection against intracellular pathogen infection. <i>Innate Immunity</i> , 2018, 24, 452-465.	2.4	28
123	Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2922.	4.1	30
124	Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages. <i>Cell</i> , 2018, 175, 442-457.e23.	28.9	198
125	Siglec-7 engagement by GBS Î²2-protein suppresses pyroptotic cell death of natural killer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 10410-10415.	7.1	38
126	CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells. <i>Leukemia</i> , 2018, 32, 2307-2315.	7.2	96
127	Lack of FcRn Impairs Natural Killer Cell Development and Functions in the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2018, 9, 2259.	4.8	28
128	Uncovering the underlying physical mechanism for cancer-immunity of MHC class I diversity. <i>Biochemical and Biophysical Research Communications</i> , 2018, 504, 532-537.	2.1	3
129	Natural Killer Cells in Liver Disease and Hepatocellular Carcinoma and the NK Cell-Based Immunotherapy. <i>Journal of Immunology Research</i> , 2018, 2018, 1-8.	2.2	105
130	PD-L1 blockade enhances anti-tumor efficacy of NK cells. <i>Oncolimmunology</i> , 2018, 7, e1509819.	4.6	104

#	ARTICLE	IF	CITATIONS
131	Memory responses by natural killer cells. <i>Journal of Leukocyte Biology</i> , 2018, 104, 1087-1096.	3.3	18
132	Poorly cytotoxic terminally differentiated CD56negCD16pos NK cells accumulate in Kenyan children with Burkitt lymphomas. <i>Blood Advances</i> , 2018, 2, 1101-1114.	5.2	45
133	Exosomes, Stem Cells and MicroRNA. <i>Advances in Experimental Medicine and Biology</i> , 2018, , .	1.6	1
134	Ultrasound-guided radiofrequency ablation enhances natural killer-mediated antitumor immunity against liver cancer. <i>Oncology Letters</i> , 2018, 15, 7014-7020.	1.8	11
135	Emerging functional markers for cancer stem cell-based therapies: Understanding signaling networks for targeting metastasis. <i>Seminars in Cancer Biology</i> , 2018, 53, 90-109.	9.6	62
136	Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. <i>Cell Stem Cell</i> , 2018, 23, 181-192.e5.	11.1	634
137	Epigenetic Mechanisms Dictating Eradication of Cancer by Natural Killer Cells. <i>Trends in Cancer</i> , 2018, 4, 553-566.	7.4	22
138	Rocaglamide enhances NK cell-mediated killing of non-small cell lung cancer cells by inhibiting autophagy. <i>Autophagy</i> , 2018, 14, 1831-1844.	9.1	62
139	Hepatoâ€centrained B220 ⁺ <scp>CD</scp> 11c ⁺ <scp>NK</scp> 1.1 ⁺ cells regulate preâ€metastatic niche formation in theÂlung. <i>EMBO Molecular Medicine</i> , 2018, 10, .	6.9	11
140	Optimized nanoparticle-mediated delivery of CRISPR-Cas9 system for B cell intervention. <i>Nano Research</i> , 2018, 11, 6270-6282.	10.4	29
142	Sweet Killers: NK Cells Need Glycolysis to Kill Tumors. <i>Cell Metabolism</i> , 2018, 28, 183-184.	16.2	12
143	Immune Landscape of Colorectal Cancer Tumor Microenvironment from Different Primary Tumor Location. <i>Frontiers in Immunology</i> , 2018, 9, 1578.	4.8	143
144	Intracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts. <i>Chemical Reviews</i> , 2018, 118, 7409-7531.	47.7	490
145	Molecular Basis for the Recognition of Herpes Simplex Virus Type 1 Infection by Human Natural Killer Cells. <i>Frontiers in Immunology</i> , 2018, 9, 183.	4.8	20
146	Acquired Natural Killer Cell Dysfunction in the Tumor Microenvironment of Classic Hodgkin Lymphoma. <i>Frontiers in Immunology</i> , 2018, 9, 267.	4.8	57
147	Engineering Approaches in Human Gamma Delta T Cells for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 1409.	4.8	55
148	Non-Cell Autonomous Effects of the Senescence-Associated Secretory Phenotype in Cancer Therapy. <i>Frontiers in Oncology</i> , 2018, 8, 164.	2.8	61
149	Modulation of anti-tumor immunity by the brainâ€™s reward system. <i>Nature Communications</i> , 2018, 9, 2723.	12.8	99

#	ARTICLE	IF	CITATIONS
150	Cellular Mechanisms Controlling Surfacing of AICL Glycoproteins, Cognate Ligands of the Activating NK Receptor NKp80. <i>Journal of Immunology</i> , 2018, 201, 1275-1286.	0.8	6
151	Dysfunction of Natural Killer Cells by FBP1-Induced Inhibition of Glycolysis during Lung Cancer Progression. <i>Cell Metabolism</i> , 2018, 28, 243-255.e5.	16.2	227
152	IL-15 Overcomes Hepatocellular Carcinoma-Induced NK Cell Dysfunction. <i>Frontiers in Immunology</i> , 2018, 9, 1009.	4.8	88
153	Exosome-Based Cell-Cell Communication in the Tumor Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2018, 6, 18.	3.7	495
154	Natural killer cell immunotherapy against multiple myeloma: Progress and possibilities. <i>Journal of Leukocyte Biology</i> , 2018, 103, 821-828.	3.3	13
155	Exosomes Function in Tumor Immune Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1056, 109-122.	1.6	36
156	Activated innate lymphoid cell populations accumulate in human tumour tissues. <i>BMC Cancer</i> , 2018, 18, 341.	2.6	85
157	Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. <i>Journal of Hematology and Oncology</i> , 2018, 11, 104.	17.0	303
158	Regulation of Immunity and Disease by the IL-1 Receptor Family Members IL-1R2 and IL-1R8. , 2018, , 225-246.		1
159	Emerging Applications of Fluorogenic and Nonfluorogenic Bifunctional Linkers. <i>Chemistry - A European Journal</i> , 2018, 24, 16484-16505.	3.3	9
160	The expanding role of murine class Ib MHC in the development and activation of Natural Killer cells. <i>Molecular Immunology</i> , 2019, 115, 31-38.	2.2	13
161	Natural killer cell-based immunotherapy: From transplantation toward targeting cancer stem cells. <i>Journal of Cellular Physiology</i> , 2019, 234, 259-273.	4.1	43
162	Beta-2 microglobulin knockout K562 cell-based artificial antigen presenting cells for <i>ex vivo</i> expansion of T lymphocytes. <i>Immunotherapy</i> , 2019, 11, 967-982.	2.0	6
163	Multifunctional nanoparticles for genetic engineering and bioimaging of natural killer (NK) cell therapeutics. <i>Biomaterials</i> , 2019, 221, 119418.	11.4	51
165	ILC regulation of T cell responses in inflammatory diseases and cancer. <i>Seminars in Immunology</i> , 2019, 41, 101284.	5.6	19
166	Cytotoxic effects of <i>ex vivo</i> -expanded natural killer cell-enriched lymphocytes (MYJ1633) against liver cancer. <i>BMC Cancer</i> , 2019, 19, 817.	2.6	11
167	Interferon beta increases NK cell cytotoxicity against tumor cells in patients with nasopharyngeal carcinoma via tumor necrosis factor apoptosis-inducing ligand. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1317-1329.	4.2	17
168	Natural Killer Cells in the Lungs. <i>Frontiers in Immunology</i> , 2019, 10, 1416.	4.8	82

#	ARTICLE	IF	CITATIONS
169	Progressive Impairment of NK Cell Cytotoxic Degranulation Is Associated With TGF- β 1 Deregulation and Disease Progression in Pancreatic Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 1354.	4.8	40
170	Selenium-containing ruthenium complex synergizes with natural killer cells to enhance immunotherapy against prostate cancer via activating TRAIL/FasL signaling. <i>Biomaterials</i> , 2019, 219, 119377.	11.4	56
171	Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors. <i>Cancers</i> , 2019, 11, 1040.	3.7	40
172	Structure-based rational design of a novel chimeric PD1-NKG2D receptor for natural killer cells. <i>Molecular Immunology</i> , 2019, 114, 108-113.	2.2	31
173	Tumor- and cytokine-primed human natural killer cells exhibit distinct phenotypic and transcriptional signatures. <i>PLoS ONE</i> , 2019, 14, e0218674.	2.5	29
174	The macrophage tetraspan MS4A4A enhances dectin-1-dependent NK cell-mediated resistance to metastasis. <i>Nature Immunology</i> , 2019, 20, 1012-1022.	14.5	75
175	Nanomedicine-Based Immunotherapy for the Treatment of Cancer Metastasis. <i>Advanced Materials</i> , 2019, 31, e1904156.	21.0	120
176	Artificial Natural Killer Cells for Specific Tumor Inhibition and Renegade Macrophage Re-Education. <i>Advanced Materials</i> , 2019, 31, e1904495.	21.0	59
177	Artificial Engineered Natural Killer Cells Combined with Antiheat Endurance as a Powerful Strategy for Enhancing Photothermal-Immunotherapy Efficiency of Solid Tumors. <i>Small</i> , 2019, 15, e1902636.	10.0	43
178	Post-translational Mechanisms Regulating NK Cell Activating Receptors and Their Ligands in Cancer: Potential Targets for Therapeutic Intervention. <i>Frontiers in Immunology</i> , 2019, 10, 2557.	4.8	20
179	CEACAM1 structure and function in immunity and its therapeutic implications. <i>Seminars in Immunology</i> , 2019, 42, 101296.	5.6	62
180	NK Cell-Fc Receptors Advance Tumor Immunotherapy. <i>Journal of Clinical Medicine</i> , 2019, 8, 1667.	2.4	17
181	Expansion processes for cell-based therapies. <i>Biotechnology Advances</i> , 2019, 37, 107455.	11.7	15
182	Natural killer cells control metastasis via structural editing of primary tumors in mice. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1721-1724.	4.2	4
183	Synergized regulation of NK cell education by NKG2A and specific Ly49 family members. <i>Nature Communications</i> , 2019, 10, 5010.	12.8	43
184	Key features and homing properties of NK cells in the liver are shaped by activated iNKT cells. <i>Scientific Reports</i> , 2019, 9, 16362.	3.3	0
185	The role of helper innate lymphoid cells in cancer. <i>Immunotherapy</i> , 2019, 11, 1067-1081.	2.0	5
186	Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia. <i>Nature Communications</i> , 2019, 10, 4869.	12.8	36

#	ARTICLE	IF	CITATIONS
187	Phagocytosis checkpoints as new targets for cancer immunotherapy. <i>Nature Reviews Cancer</i> , 2019, 19, 568-586.	28.4	557
188	A Natural Impact: NK Cells at the Intersection of Cancer and HIV Disease. <i>Frontiers in Immunology</i> , 2019, 10, 1850.	4.8	21
189	Imbalance of Genes Encoding Natural Killer Immunoglobulin-Like Receptors and Human Leukocyte Antigen in Patients With Biliary Cancer. <i>Gastroenterology</i> , 2019, 157, 1067-1080.e9.	1.3	19
190	Astragaloside III Enhances Anti-Tumor Response of NK Cells by Elevating NKG2D and IFN- γ . <i>Frontiers in Pharmacology</i> , 2019, 10, 898.	3.5	17
191	Immunobiology of cholangiocarcinoma. <i>JHEP Reports</i> , 2019, 1, 297-311.	4.9	79
192	Immune Checkpoint Blockade. <i>Methods in Molecular Biology</i> , 2019, , .	0.9	0
193	Immune evasion by TGF β -induced miR-183 repression of MICA/B expression in human lung tumor cells. <i>Oncotmunology</i> , 2019, 8, e1557372.	4.6	30
194	Bioinspired Preservation of Natural Killer Cells for Cancer Immunotherapy. <i>Advanced Science</i> , 2019, 6, 1802045.	11.2	33
195	Survival of Ovarian Cancer Patients Is Independent of the Presence of DC and T Cell Subsets in Ascites. <i>Frontiers in Immunology</i> , 2019, 9, 3156.	4.8	18
196	Evaluating Antibody-Dependent Cell-Mediated Cytotoxicity by Chromium Release Assay. <i>Methods in Molecular Biology</i> , 2019, 1913, 167-179.	0.9	1
197	Evaluating Antibody-Dependent Cell-Mediated Cytotoxicity by Flow Cytometry. <i>Methods in Molecular Biology</i> , 2019, 1913, 181-194.	0.9	5
198	Cell-based immunotherapy in gynecologic malignancies. <i>Current Opinion in Obstetrics and Gynecology</i> , 2019, 31, 43-48.	2.0	3
199	Therapeutic Modulation of Autophagy in Leukaemia and Lymphoma. <i>Cells</i> , 2019, 8, 103.	4.1	37
200	ILCs in hematologic malignancies: Tumor cell killers and tissue healers. <i>Seminars in Immunology</i> , 2019, 41, 101279.	5.6	13
201	CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2839.	4.1	34
202	An Historical Overview: The Discovery of How NK Cells Can Kill Enemies, Recruit Defense Troops, and More. <i>Frontiers in Immunology</i> , 2019, 10, 1415.	4.8	57
203	Induced Pluripotent Stem Cell (iPSC)-Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 261-268.	2.3	72
204	CD155 expression in human breast cancer: Clinical significance and relevance to natural killer cell infiltration. <i>Life Sciences</i> , 2019, 231, 116543.	4.3	50

#	ARTICLE	IF	CITATIONS
205	In Situ Modification of the Tumor Cell Surface with Immunomodulating Nanoparticles for Effective Suppression of Tumor Growth in Mice. <i>Advanced Materials</i> , 2019, 31, e1902542.	21.0	58
206	Hematological Malignancy-Derived Small Extracellular Vesicles and Tumor Microenvironment: The Art of Turning Foes into Friends. <i>Cells</i> , 2019, 8, 511.	4.1	26
207	Human NK cell receptor KIR2DS4 detects a conserved bacterial epitope presented by HLA-C. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 12964-12973.	7.1	59
208	Derivation of mimetic α T cells endowed with cancer recognition receptors from reprogrammed α T cell. <i>PLoS ONE</i> , 2019, 14, e0216815.	2.5	22
209	Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities. <i>Frontiers in Immunology</i> , 2019, 10, 1205.	4.8	292
210	Cellular therapy for acute myeloid Leukemia – Current status and future prospects. <i>Blood Reviews</i> , 2019, 37, 100578.	5.7	49
211	Potential of NK cells in multiple Myeloma therapy. <i>Expert Review of Hematology</i> , 2019, 12, 425-435.	2.2	13
212	Natural killer cells involved in tumour immune escape of hepatocellular carcinomas. <i>International Immunopharmacology</i> , 2019, 73, 10-16.	3.8	16
213	The IRE1 endoplasmic reticulum stress sensor activates natural killer cell immunity in part by regulating c-Myc. <i>Nature Immunology</i> , 2019, 20, 865-878.	14.5	120
214	Beyond cDC1: Emerging Roles of DC Crosstalk in Cancer Immunity. <i>Frontiers in Immunology</i> , 2019, 10, 1014.	4.8	74
215	Human Gut-Associated Natural Killer Cells in Health and Disease. <i>Frontiers in Immunology</i> , 2019, 10, 961.	4.8	101
216	Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering. <i>Human Gene Therapy Methods</i> , 2019, 30, 102-120.	2.1	43
217	Hollow mesoporous ruthenium nanoparticles conjugated bispecific antibody for targeted anti-colorectal cancer response of combination therapy. <i>Nanoscale</i> , 2019, 11, 9661-9678.	5.6	46
218	Dysregulation of Natural Killer Cells in Obesity. <i>Cancers</i> , 2019, 11, 573.	3.7	76
219	Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2057.	4.1	17
220	Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions. <i>Frontiers in Immunology</i> , 2019, 10, 910.	4.8	54
221	NK cells: An attractive candidate for cancer therapy. <i>Journal of Cellular Physiology</i> , 2019, 234, 19352-19365.	4.1	55
222	When CAR Meets Stem Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1825.	4.1	7

#	ARTICLE	IF	CITATIONS
223	Current Concepts in Natural Killer Cell Biology and Application to Drug Safety Assessments. Toxicological Sciences, 2019, 170, 10-19.	3.1	4
224	Natural killer cells as a promising therapeutic target for cancer immunotherapy. Archives of Pharmacal Research, 2019, 42, 591-606.	6.3	29
225	Ex vivo-expanded highly purified natural killer cells in combination with temozolomide induce antitumor effects in human glioblastoma cells in vitro. PLoS ONE, 2019, 14, e0212455.	2.5	31
226	The tumour microenvironment and immune milieu of cholangiocarcinoma. Liver International, 2019, 39, 63-78.	3.9	109
227	The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine. Journal of Autoimmunity, 2019, 100, 17-26.	6.5	33
228	Tailoring Nanomaterials for Targeting Tumor-Associated Macrophages. Advanced Materials, 2019, 31, e1808303.	21.0	223
229	Harnessing the innate immune system and local immunological microenvironment to treat colorectal cancer. British Journal of Cancer, 2019, 120, 871-882.	6.4	62
230	Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy. Thyroid, 2019, 29, 979-992.	4.5	71
231	Induction of human pluripotent stem cell-derived natural killer cells for immunotherapy under chemically defined conditions. Biochemical and Biophysical Research Communications, 2019, 515, 1-8.	2.1	21
232	Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients. Molecular Therapy, 2019, 27, 1114-1125.	8.2	168
233	Cognate Interaction With CD4+ T Cells Instructs Tumor-Associated Macrophages to Acquire M1-Like Phenotype. Frontiers in Immunology, 2019, 10, 219.	4.8	47
234	Innate lymphoid cells in intestinal cancer development. Seminars in Immunology, 2019, 41, 101267.	5.6	22
235	Radiochemotherapy combined with NK cell transfer followed by second-line PD-1 inhibition in a patient with NSCLC stage IIIb inducing long-term tumor control: a case study. Strahlentherapie Und Onkologie, 2019, 195, 352-361.	2.0	32
236	The Effects of AHCC®, a Standardized Extract of Cultured <i>Lentinula edodes</i> Mycelia, on Natural Killer and T Cells in Health and Disease: Reviews on Human and Animal Studies. Journal of Immunology Research, 2019, 2019, 1-7.	2.2	18
237	Engineered human pluripotent stem cell-derived natural killer cells: the next frontier for cancer immunotherapy. Blood Science, 2019, 1, 4-11.	0.9	10
238	Microfluidics-assisted multiplexed biomarker detection for in situ mapping of immune cells in tumor sections. Microsystems and Nanoengineering, 2019, 5, 59.	7.0	24
239	Critical Roles of Balanced Innate Lymphoid Cell Subsets in Intestinal Homeostasis, Chronic Inflammation, and Cancer. Journal of Immunology Research, 2019, 2019, 1-10.	2.2	9
240	Single-cell transcriptomics of the naked mole-rat reveals unexpected features of mammalian immunity. PLoS Biology, 2019, 17, e3000528.	5.6	80

#	ARTICLE	IF	CITATIONS
241	Mitochondrial fragmentation limits NK cell-based tumor immunosurveillance. <i>Nature Immunology</i> , 2019, 20, 1656-1667.	14.5	156
242	Anti-Î±FR CAR-engineered NK-92 Cells Display Potent Cytotoxicity Against Î±FR-positive Ovarian Cancer. <i>Journal of Immunotherapy</i> , 2019, 42, 284-296.	2.4	48
243	Natural killer cell-based immunotherapy: a new fighter against melanoma?. <i>Melanoma Research</i> , 2019, 29, 208-211.	1.2	2
244	Deficient Natural Killer Cell Nkp30â€Mediated Function and Altered NCR3 Splice Variants in Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 1165-1179.	7.3	48
245	Direct RIGâ€ activation in human NK cells induces TRAILâ€dependent cytotoxicity toward autologous melanoma cells. <i>International Journal of Cancer</i> , 2019, 144, 1645-1656.	5.1	23
246	The rise of human stem cell-derived natural killer cells for cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 141-148.	3.1	19
247	Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 49.	4.1	35
248	Grainyhead-like-2 confers NK-sensitivity through interactions with epigenetic modifiers. <i>Molecular Immunology</i> , 2019, 105, 137-149.	2.2	19
249	Natural Killer Cells in Cancer Immunotherapy. <i>Annual Review of Cancer Biology</i> , 2019, 3, 77-103.	4.5	122
250	PEGylated silver nanoparticles from <i>Sesbania aegyptiaca</i> exhibit immunomodulatory and anti-cancer activity. <i>Materials Research Express</i> , 2019, 6, 035402.	1.6	5
251	The clinical role of the TME in solid cancer. <i>British Journal of Cancer</i> , 2019, 120, 45-53.	6.4	380
252	Intratumoral IL17-producing cells infiltration correlate with antitumor immune contexture and improved response to adjuvant chemotherapy in gastric cancer. <i>Annals of Oncology</i> , 2019, 30, 266-273.	1.2	48
253	Adoptive cellular therapies: the current landscape. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 449-461.	2.8	261
254	Circulating innate immune markers and outcomes in treatment-naïve advanced nonâ€small cell lung cancer patients. <i>European Journal of Cancer</i> , 2019, 108, 88-96.	2.8	36
255	Humanized anti-CD123 antibody facilitates NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of Hodgkin lymphoma targets via ARF6/PLD-1. <i>Blood Cancer Journal</i> , 2019, 9, 6.	6.2	13
256	Development of innate immune cells from human pluripotent stem cells. <i>Experimental Hematology</i> , 2019, 71, 13-23.	0.4	46
257	Targeting NKG2A to elucidate natural killer cell ontogenesis and to develop novel immuneâ€therapeutic strategies in cancer therapy. <i>Journal of Leukocyte Biology</i> , 2019, 105, 1243-1251.	3.3	37
258	Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety. <i>Methods</i> , 2019, 154, 102-117.	3.8	136

#	ARTICLE	IF	CITATIONS
259	B7H6 is a functional ligand for NKp30 in rat and cattle and determines NKp30 reactivity toward human cancer cell lines. <i>European Journal of Immunology</i> , 2019, 49, 54-65.	2.9	9
260	CD8 ⁺ cytotoxic T lymphocytes in cancer immunotherapy: A review. <i>Journal of Cellular Physiology</i> , 2019, 234, 8509-8521.	4.1	1,012
261	Natural killer cells and anti-tumor immunity. <i>Molecular Immunology</i> , 2019, 110, 40-47.	2.2	38
262	Neutrophils: Homing in on the myeloid mechanisms of metastasis. <i>Molecular Immunology</i> , 2019, 110, 69-76.	2.2	30
263	Perioperative analgesia with parecoxib sodium improves postoperative pain and immune function in patients undergoing hepatectomy for hepatocellular carcinoma. <i>Journal of Evaluation in Clinical Practice</i> , 2020, 26, 992-1000.	1.8	16
264	Immunity, Hypoxia, and Metabolism—the MÃ©nage Å Trois of Cancer: Implications for Immunotherapy. <i>Physiological Reviews</i> , 2020, 100, 1-102.	28.8	190
265	Evaluation of NK cell cytotoxic activity against malignant cells by the calcein assay. <i>Methods in Enzymology</i> , 2020, 631, 483-495.	1.0	10
266	NK cell-based therapeutics for lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 23-33.	3.1	52
267	Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach. <i>Journal of the National Cancer Institute</i> , 2020, 112, 708-719.	6.3	111
268	Progression or suppression: Two sides of the innate lymphoid cells in cancer. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 2739-2755.	2.6	6
269	New Approaches on Cancer Immunotherapy. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a036863.	6.2	17
270	Myeloid Cells in Metastasis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a038026.	6.2	29
271	Anti-tumor and immunomodulatory activity of the aqueous extract of <i>Sarcodon imbricatus</i> in vitro and in vivo. <i>Food and Function</i> , 2020, 11, 1110-1121.	4.6	14
272	NK cells for cancer immunotherapy. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 200-218.	46.4	709
273	Natural Killer Cell Regulation of B Cell Responses in the Context of Viral Infection. <i>Viral Immunology</i> , 2020, 33, 334-341.	1.3	17
274	Patrolling Monocytes Control NK Cell Expression of Activating and Stimulatory Receptors to Curtail Lung Metastases. <i>Journal of Immunology</i> , 2020, 204, 192-198.	0.8	28
275	Cell Reprogramming for Immunotherapy. <i>Methods in Molecular Biology</i> , 2020, , .	0.9	2
276	Overexpression of Mitochondrial IF1 Prevents Metastatic Disease of Colorectal Cancer by Enhancing Anoikis and Tumor Infiltration of NK Cells. <i>Cancers</i> , 2020, 12, 22.	3.7	31

#	ARTICLE	IF	CITATIONS
277	Fibronectin in Cancer: Friend or Foe. <i>Cells</i> , 2020, 9, 27.	4.1	108
278	Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma. <i>Frontiers in Immunology</i> , 2020, 11, 2105.	4.8	164
279	Cord-Blood Natural Killer Cell-Based Immunotherapy for Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 584099.	4.8	20
280	Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions. , 2020, 8, e001054.		54
281	OMIP 070: NKp46-Based 27-Color Phenotyping to Define Natural Killer Cells Isolated From Human Tumor Tissues. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2020, 97, 1052-1056.	1.5	4
283	Prognostic value and immunological role of PDCD1 gene in pan-cancer. <i>International Immunopharmacology</i> , 2020, 89, 107080.	3.8	52
284	NK cells in the tumor microenvironment: Prognostic and theranostic impact. Recent advances and trends. <i>Seminars in Immunology</i> , 2020, 48, 101407.	5.6	31
285	Hhex Directly Represses BIM-Dependent Apoptosis to Promote NK Cell Development and Maintenance. <i>Cell Reports</i> , 2020, 33, 108285.	6.4	7
286	Adapter chimeric antigen receptor (AdCAR)-engineered NK-92 cells: an off-the-shelf cellular therapeutic for universal tumor targeting. <i>Oncolimmunology</i> , 2020, 9, 1825177.	4.6	26
287	Predicting combinations of immunomodulators to enhance dendritic cell-based vaccination based on a hybrid experimental and computational platform. <i>Computational and Structural Biotechnology Journal</i> , 2020, 18, 2217-2227.	4.1	0
288	The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies. <i>Nature Immunology</i> , 2020, 21, 835-847.	14.5	243
289	Tumor microenvironment and future targets of immunotherapy in breast cancer. <i>Translational Breast Cancer Research</i> , 0, 1, 6-6.	0.4	2
290	Utilization of CRISPR/Cas9 gene editing in cellular therapies for lymphoid malignancies. <i>Immunology Letters</i> , 2020, 226, 71-82.	2.5	9
291	The interactions and communications in tumor resistance to radiotherapy: Therapy perspectives. <i>International Immunopharmacology</i> , 2020, 87, 106807.	3.8	46
292	Antagonistic Inflammatory Phenotypes Dictate Tumor Fate and Response to Immune Checkpoint Blockade. <i>Immunity</i> , 2020, 53, 1215-1229.e8.	14.3	131
293	The Crosstalk Between Tumor-Associated Macrophages (TAMs) and Tumor Cells and the Corresponding Targeted Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 590941.	2.8	117
294	Next-generation cell therapies: the emerging role of CAR-NK cells. <i>Blood Advances</i> , 2020, 4, 5868-5876.	5.2	85
295	MIF-Dependent Control of Tumor Immunity. <i>Frontiers in Immunology</i> , 2020, 11, 609948.	4.8	59

#	ARTICLE	IF	CITATIONS
296	PBRM1 and the glycosylphosphatidylinositol biosynthetic pathway promote tumor killing mediated by MHC-unrestricted cytotoxic lymphocytes. <i>Science Advances</i> , 2020, 6, .	10.3	8
297	Generation of Mesenchymal Stromal Cells with Low Immunogenicity from Human PBMC-Derived β 2 Microglobulin Knockout Induced Pluripotent Stem Cells. <i>Cell Transplantation</i> , 2020, 29, 096368972096552.	2.5	9
298	Functionally Relevant Differences in Plasma Fatty Acid Composition and Expression of Cytotoxic and Inhibitory NK Cell Receptors between Healthy Young and Healthy Elder Adults. <i>Nutrients</i> , 2020, 12, 3641.	4.1	4
299	Next-generation cell therapies: the emerging role of CAR-NK cells. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 570-578.	2.5	27
300	Immunotherapy Targeting Tumor-Associated Macrophages. <i>Frontiers in Medicine</i> , 2020, 7, 583708.	2.6	15
301	Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance. <i>Scientific Reports</i> , 2020, 10, 19398.	3.3	23
302	The Role of Natural Killer Cells in the Immune Response in Kidney Transplantation. <i>Frontiers in Immunology</i> , 2020, 11, 1454.	4.8	32
303	Inflammatory Cells in Diffuse Large B Cell Lymphoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 2418.	2.4	29
304	Conditional Deletion of PGC-1 β Results in Energetic and Functional Defects in NK Cells. <i>IScience</i> , 2020, 23, 101454.	4.1	11
305	Harnessing Natural Killer Cell Function for Genitourinary Cancers. <i>Urologic Clinics of North America</i> , 2020, 47, 433-442.	1.8	6
306	NFE2L2 Is a Potential Prognostic Biomarker and Is Correlated with Immune Infiltration in Brain Lower Grade Glioma: A Pan-Cancer Analysis. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-26.	4.0	69
307	Novel cytokine-antibody fusion protein, N-820, to enhance the functions of ex vivo expanded natural killer cells against Burkitt lymphoma. , 2020, 8, e001238.		11
308	Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 250.	17.1	86
309	NK cells as adoptive cellular therapy for hematological malignancies: Advantages and hurdles. <i>Seminars in Hematology</i> , 2020, 57, 175-184.	3.4	10
310	MYC as a Multifaceted Regulator of Tumor Microenvironment Leading to Metastasis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7710.	4.1	54
311	Targeted Natural Killer Cell-Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial. <i>Clinical Cancer Research</i> , 2020, 26, 5368-5379.	7.0	42
312	Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. <i>Nature Communications</i> , 2020, 11, 4810.	12.8	95
313	Targeting MHC Regulation Using Polycyclic Polyprenylated Acylphloroglucinols Isolated from <i>Garcinia bancana</i> . <i>Biomolecules</i> , 2020, 10, 1266.	4.0	10

#	ARTICLE	IF	CITATIONS
314	Natural-Killer-Cell-Inspired Nanorobots with Aggregation-Induced Emission Characteristics for Near-Infrared-II Fluorescence-Guided Glioma Theranostics. <i>ACS Nano</i> , 2020, 14, 11452-11462.	14.6	156
315	Carotenoids in Cancer Metastasis—Status Quo and Outlook. <i>Biomolecules</i> , 2020, 10, 1653.	4.0	32
316	Physical Characterization of Colorectal Cancer Spheroids and Evaluation of NK Cell Infiltration Through a Flow-Based Analysis. <i>Frontiers in Immunology</i> , 2020, 11, 564887.	4.8	20
317	NK cells in pancreatic cancer demonstrate impaired cytotoxicity and a regulatory IL-10 phenotype. <i>Onc Immunology</i> , 2020, 9, 1845424.	4.6	38
318	Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2020, 13, 168.	17.0	114
319	Assessment of NK Cell Activity Based on NK Cell-Specific Receptor Synergy in Peripheral Blood Mononuclear Cells and Whole Blood. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8112.	4.1	2
320	Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer. <i>Cancer Research</i> , 2021, 81, 158-173.	0.9	85
321	Bench-to-bedside translation of interleukin-15 for immunotherapy: principles and challenges. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 895-898.	5.0	5
322	Donor Lymphocyte—Derived Natural Killer Cells Control MHC Class II—Negative Melanoma. <i>Cancer Immunology Research</i> , 2020, 8, 756-768.	3.4	3
323	CARs: Beyond T Cells and T Cell-Derived Signaling Domains. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3525.	4.1	19
324	The immunoregulatory function of polyphenols: implications in cancer immunity. <i>Journal of Nutritional Biochemistry</i> , 2020, 85, 108428.	4.2	20
325	Metabolic Reprogramming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity. <i>Cell Stem Cell</i> , 2020, 27, 224-237.e6.	11.1	177
326	IL-6-induced CD39 expression on tumor-infiltrating NK cells predicts poor prognosis in esophageal squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2371-2380.	4.2	30
327	The cancer—natural killer cell immunity cycle. <i>Nature Reviews Cancer</i> , 2020, 20, 437-454.	28.4	308
328	Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies. <i>Stem Cell Research and Therapy</i> , 2020, 11, 234.	5.5	55
329	PBX1 promotes development of natural killer cells by binding directly to the <i>Nfil3</i> promoter. <i>FASEB Journal</i> , 2020, 34, 6479-6492.	0.5	13
330	Cyto-Immuno-Therapy for Cancer: A Pathway Elicited by Tumor-Targeted, Cytotoxic Drug-Packaged Bacterially Derived Nanocells. <i>Cancer Cell</i> , 2020, 37, 354-370.e7.	16.8	34
332	Comprehensive review of targeted therapy for colorectal cancer. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 22.	17.1	853

#	ARTICLE	IF	CITATIONS
333	Equipping Natural Killer Cells with Specific Targeting and Checkpoint Blocking Aptamers for Enhanced Adoptive Immunotherapy in Solid Tumors. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 12022-12028.	13.8	114
334	Exploiting antibody biology for the treatment of cancer. <i>Immunotherapy</i> , 2020, 12, 255-267.	2.0	7
335	Pleiotropic Role and Bidirectional Immunomodulation of Innate Lymphoid Cells in Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 3111.	4.8	24
336	Development of an Immune Infiltration-Related Prognostic Scoring System Based on the Genomic Landscape Analysis of Glioblastoma Multiforme. <i>Frontiers in Oncology</i> , 2020, 10, 154.	2.8	20
337	ULBP1 Is Elevated in Human Hepatocellular Carcinoma and Predicts Outcome. <i>Frontiers in Oncology</i> , 2020, 10, 971.	2.8	10
338	Real-time monitoring of oncolytic VSV properties in a novel in vitro microphysiological system containing 3D multicellular tumor spheroids. <i>PLoS ONE</i> , 2020, 15, e0235356.	2.5	1
339	Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer. <i>Cancers</i> , 2020, 12, 1761.	3.7	8
340	Roles of NK Cell Receptors 2B4 (CD244), CS1 (CD319), and LLT1 (CLEC2D) in Cancer. <i>Cancers</i> , 2020, 12, 1755.	3.7	37
341	Immunogenomic Landscape of Hematological Malignancies. <i>Cancer Cell</i> , 2020, 38, 380-399.e13.	16.8	109
342	Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors. <i>Onc Immunology</i> , 2020, 9, 1777064.	4.6	25
343	Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals. <i>Biomedicines</i> , 2020, 8, 175.	3.2	8
344	Understanding the Complexity of the Tumor Microenvironment in K-ras Mutant Lung Cancer: Finding an Alternative Path to Prevention and Treatment. <i>Frontiers in Oncology</i> , 2019, 9, 1556.	2.8	27
345	Systemic immune-inflammation index predicted overall survival and radiosensitivity in advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2020, 16, 103-115.	2.4	14
346	Tissue Determinants of Human NK Cell Development, Function, and Residence. <i>Cell</i> , 2020, 180, 749-763.e13.	28.9	242
347	Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer. <i>Biochemical and Biophysical Research Communications</i> , 2020, 524, 96-102.	2.1	57
348	CD16 pre-ligation by defucosylated tumor-targeting mAb sensitizes human NK cells to I^3C cytokine stimulation via PI3K/mTOR axis. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 501-512.	4.2	8
349	Interstitial serum albumin empowers osteosarcoma cells with FAIM2 transcription to obtain viability via dedifferentiation. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2020, 56, 129-144.	1.5	4
350	Screening and Identifying Immune-Related Cells and Genes in the Tumor Microenvironment of Bladder Urothelial Carcinoma: Based on TCGA Database and Bioinformatics. <i>Frontiers in Oncology</i> , 2019, 9, 1533.	2.8	53

#	ARTICLE	IF	CITATIONS
351	Rapid isolation and enrichment of mouse NK cells for experimental purposes. <i>Methods in Enzymology</i> , 2020, 631, 257-275.	1.0	4
352	Engineered nanoparticles to enhance natural killer cell activity towards onco-immunotherapy: a review. <i>Archives of Pharmacal Research</i> , 2020, 43, 32-45.	6.3	21
353	NK Cell-Based Immunotherapy in Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 316.	3.7	20
354	A novel bispecific chimeric PD1-DAP10/NKG2D receptor augments NK92-cell therapy efficacy for human gastric cancer SGC-7901 cell. <i>Biochemical and Biophysical Research Communications</i> , 2020, 523, 745-752.	2.1	15
355	Cancer immunotherapy: Pros, cons and beyond. <i>Biomedicine and Pharmacotherapy</i> , 2020, 124, 109821.	5.6	337
356	Skin-Resident Innate Lymphoid Cells “Cutaneous Innate Guardians and Regulators. <i>Trends in Immunology</i> , 2020, 41, 100-112.	6.8	45
357	Mechanisms of Natural Killer Cell Evasion Through Viral Adaptation. <i>Annual Review of Immunology</i> , 2020, 38, 511-539.	21.8	22
358	The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3125.	4.1	76
359	Induced Pluripotent Stem Cells: Reprogramming Platforms and Applications in Cell Replacement Therapy. <i>BioResearch Open Access</i> , 2020, 9, 121-136.	2.6	50
360	Mechanisms of resistance to T cell-based immunotherapy in head and neck cancer. <i>Head and Neck</i> , 2020, 42, 2722-2733.	2.0	16
361	EPHA5 mutation impairs natural killer cell-mediated cytotoxicity against non-small lung cancer cells and promotes cancer cell migration and invasion. <i>Molecular and Cellular Probes</i> , 2020, 52, 101566.	2.1	13
362	Mechanism of tumor cells escaping from immune surveillance of NK cells. <i>Immunopharmacology and Immunotoxicology</i> , 2020, 42, 187-198.	2.4	17
363	IL-12 regulates the expansion, phenotype, and function of murine NK cells activated by IL-15 and IL-18. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1699-1712.	4.2	39
364	Harnessing the Formation of Natural Killer-Tumor Cell Immunological Synapses for Enhanced Therapeutic Effect in Solid Tumors. <i>Advanced Materials</i> , 2020, 32, e2000020.	21.0	29
365	Equipping Natural Killer Cells with Specific Targeting and Checkpoint Blocking Aptamers for Enhanced Adoptive Immunotherapy in Solid Tumors. <i>Angewandte Chemie</i> , 2020, 132, 12120-12126.	2.0	17
366	PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1505-1517.	4.2	58
367	Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity. <i>Blood</i> , 2020, 135, 399-410.	1.4	166
368	Natural-Killer-Derived Extracellular Vesicles: Immune Sensors and Interactors. <i>Frontiers in Immunology</i> , 2020, 11, 262.	4.8	87

#	ARTICLE	IF	CITATIONS
369	Platelet-Leukocyte Interplay in Cancer Development and Progression. <i>Cells</i> , 2020, 9, 855.	4.1	63
370	The Tumor Microenvironment in Cholangiocarcinoma Progression. <i>Hepatology</i> , 2021, 73, 75-85.	7.3	100
371	Liver Cancer Immunity. <i>Hepatology</i> , 2021, 73, 86-103.	7.3	52
372	TGFÎ² biology in cancer progression and immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 9-34.	27.6	420
373	Regulatory functions of NK cells during infections and cancer. <i>Journal of Leukocyte Biology</i> , 2021, 109, 185-194.	3.3	28
374	Immunomodulatory effects of cytokine-induced expansion of cytotoxic lymphocytes in a mouse model of lupus-like disease. <i>Cytotherapy</i> , 2021, 23, 37-45.	0.7	2
375	Immune evasion mechanisms in acute myeloid leukemia: A focus on immune checkpoint pathways. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103164.	4.4	40
376	The role of natural killer cell in gastrointestinal cancer: killer or helper. <i>Oncogene</i> , 2021, 40, 717-730.	5.9	54
377	Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer. <i>Cancer Discovery</i> , 2021, 11, 45-58.	9.4	128
378	Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement. <i>Journal of Immunology</i> , 2021, 206, 225-236.	0.8	32
379	Arsenite suppresses IL-2-dependent tumoricidal activities of natural killer cells. <i>Toxicology and Applied Pharmacology</i> , 2021, 412, 115353.	2.8	6
380	Histone deacetylase 8 inhibition suppresses mantle cell lymphoma viability while preserving natural killer cell function. <i>Biochemical and Biophysical Research Communications</i> , 2021, 534, 773-779.	2.1	13
381	Emerging immunotherapies for metastasis. <i>British Journal of Cancer</i> , 2021, 124, 37-48.	6.4	32
382	Exosomes as mediators of immune regulation and immunotherapy in cancer. <i>FEBS Journal</i> , 2021, 288, 10-35.	4.7	110
383	Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. <i>Blood</i> , 2021, 137, 624-636.	1.4	147
384	In vivo Anti-Cancer Effects of Resveratrol Mediated by NK Cell Activation. <i>Journal of Innate Immunity</i> , 2021, 13, 94-106.	3.8	29
385	Nanomedicines as Multifunctional Modulators of Melanoma Immune Microenvironment. <i>Advanced Therapeutics</i> , 2021, 4, 2000147.	3.2	2
386	Nano-immunotherapy: Overcoming tumour immune evasion. <i>Seminars in Cancer Biology</i> , 2021, 69, 238-248.	9.6	47

#	ARTICLE	IF	CITATIONS
387	Depletion of NK Cells Resistant to Ionizing Radiation Increases Mutations in Mice After Whole-body Irradiation. <i>In Vivo</i> , 2021, 35, 1507-1513.	1.3	6
388	Dysregulation of Metabolic Pathways in Circulating Natural Killer Cells Isolated from Inflammatory Bowel Disease Patients. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1316-1325.	1.3	18
389	NK cells and oncolytic viruses in cancer therapy. , 2021, , 53-62.		0
390	Multifunctional Applications of Engineered Extracellular Vesicles in the Treatment of Cancer. <i>Endocrinology</i> , 2021, 162, .	2.8	16
391	Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110180.	3.2	10
392	Biohybrid Nanosystems for Cancer Treatment: Merging the Best of Two Worlds. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1295, 135-162.	1.6	0
393	A robust platform for expansion and genome editing of primary human natural killer cells. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	43
394	Lipid Metabolism in Tumor-Associated Natural Killer Cells. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1316, 71-85.	1.6	9
395	Neoadjuvant immunotherapy in resectable head and neck cancer: oral cavity carcinoma as a potential research model. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592098406.	3.2	8
396	The Interplay of Exosomes and NK Cells in Cancer Biology. <i>Cancers</i> , 2021, 13, 473.	3.7	30
397	Targeting CD155 by rediocide-A overcomes tumour immuno-resistance to natural killer cells. <i>Pharmaceutical Biology</i> , 2021, 59, 47-53.	2.9	4
398	Next-Generation Immunotherapies to Improve Anticancer Immunity. <i>Frontiers in Pharmacology</i> , 2020, 11, 566401.	3.5	8
399	Blood microbiota diversity determines response of advanced colorectal cancer to chemotherapy combined with adoptive T cell immunotherapy. <i>Onc Immunology</i> , 2021, 10, 1976953.	4.6	13
400	Immune System Efficiency in Cancer and the Microbiota Influence. <i>Pathobiology</i> , 2021, 88, 170-186.	3.8	14
401	Unraveling the Role of Innate Lymphoid Cells in Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 320.	3.7	6
402	Immunotherapy in cholangiocarcinoma. <i>Current Opinion in Gastroenterology</i> , 2021, 37, 105-111.	2.3	10
403	Implications of microgravity-induced cell signaling alterations upon cancer cell growth, invasiveness, metastatic potential, and control by host immunity. <i>International Review of Cell and Molecular Biology</i> , 2021, 361, 107-164.	3.2	5
404	NK cells in brain tumors: From biology to treatment. , 2021, , 477-502.		1

#	ARTICLE	IF	CITATIONS
405	To betray or to fight? The dual identity of the mitochondria in cancer. <i>Future Oncology</i> , 2021, 17, 723-743.	2.4	7
406	Natural Killer Anti-Tumor Activity Can Be Achieved by In Vitro Incubation With Heat-Killed BCG. <i>Frontiers in Immunology</i> , 2021, 12, 622995.	4.8	14
407	Î2-Glucan-Induced IL-10 Secretion by Monocytes Triggers Porcine NK Cell Cytotoxicity. <i>Frontiers in Immunology</i> , 2021, 12, 634402.	4.8	11
408	Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 614332.	2.8	33
409	A randomized placebo-controlled phase I clinical trial to evaluate the immunomodulatory activities of <i>Atractylodes lancea</i> (Thunb) DC. in healthy Thai subjects. <i>BMC Complementary Medicine and Therapies</i> , 2021, 21, 61.	2.7	12
410	Novel TLR 7/8 agonists for improving NK cell mediated antibody-dependent cellular cytotoxicity (ADCC). <i>Scientific Reports</i> , 2021, 11, 3346.	3.3	17
411	Killing the Invaders: NK Cell Impact in Tumors and Anti-Tumor Therapy. <i>Cancers</i> , 2021, 13, 595.	3.7	22
412	Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Frontiers in Oncology</i> , 2021, 11, 624742.	2.8	19
414	Immunomodulating nano-adaptors potentiate antibody-based cancer immunotherapy. <i>Nature Communications</i> , 2021, 12, 1359.	12.8	64
415	Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression. <i>Cancers</i> , 2021, 13, 1353.	3.7	22
416	Virus-specific NK cell memory. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	15
417	Cellular Immunotherapy Targeting Cancer Stem Cells: Preclinical Evidence and Clinical Perspective. <i>Cells</i> , 2021, 10, 543.	4.1	14
418	Peripheral immune profile of children with <i>Talaromyces marneffe</i> infections: a retrospective analysis of 21 cases. <i>BMC Infectious Diseases</i> , 2021, 21, 287.	2.9	13
419	The role of exosomes in tumour immunity under radiotherapy: eliciting abscopal effects?. <i>Biomarker Research</i> , 2021, 9, 22.	6.8	13
420	Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics. <i>Antibodies</i> , 2021, 10, 13.	2.5	21
421	Human NK Cells in Autologous Hematopoietic Stem Cell Transplantation for Cancer Treatment. <i>Cancers</i> , 2021, 13, 1589.	3.7	7
422	Mesenchymal stromal cell-dependent immunoregulation in chemically-induced acute liver failure. <i>World Journal of Stem Cells</i> , 2021, 13, 208-220.	2.8	3
423	Leveraging microenvironmental synthetic lethality to treat cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	17

#	ARTICLE	IF	CITATIONS
424	Hypoxia-Driven HIF-1 α Activation Reprograms Pre-Activated NK Cells towards Highly Potent Effector Phenotypes via ERK/STAT3 Pathways. <i>Cancers</i> , 2021, 13, 1904.	3.7	20
425	KIF11 Serves as an Independent Prognostic Factor and Therapeutic Target for Patients With Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 670218.	2.8	15
426	Innate Immune Checkpoint Inhibitors: The Next Breakthrough in Medical Oncology?. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 961-974.	4.1	58
427	Double Insurance for OC: miRNA-Mediated Platinum Resistance and Immune Escape. <i>Frontiers in Immunology</i> , 2021, 12, 641937.	4.8	5
428	The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma. <i>Vaccines</i> , 2021, 9, 422.	4.4	8
429	Coexistence of inhibitory and activating killer-cell immunoglobulin-like receptors to the same cognate HLA-C2 and Bw4 ligands confer breast cancer risk. <i>Scientific Reports</i> , 2021, 11, 7932.	3.3	6
430	GSK-3 β Inhibition in Drug-Resistant CML Cells Promotes Susceptibility to NK Cell-Mediated Lysis in an NKG2D- and NKP30-Dependent Manner. <i>Cancers</i> , 2021, 13, 1802.	3.7	2
431	Delivery technologies to engineer natural killer cells for cancer immunotherapy. <i>Cancer Gene Therapy</i> , 2021, 28, 947-959.	4.6	20
432	Autophagy Process in Trophoblast Cells Invasion and Differentiation: Similitude and Differences With Cancer Cells. <i>Frontiers in Oncology</i> , 2021, 11, 637594.	2.8	14
433	A novel immune-related prognostic signature in epithelial ovarian carcinoma. <i>Aging</i> , 2021, 13, 10289-10311.	3.1	8
434	Chimeric antigen receptor-engineered natural killer cells: a promising cancer immunotherapy. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 643-659.	3.0	5
435	Genetically engineered oncolytic bacteria as drug delivery systems for targeted cancer theranostics. <i>Acta Biomaterialia</i> , 2021, 124, 72-87.	8.3	29
436	Immuno-Oncological Biomarkers for Squamous Cell Cancer of the Head and Neck: Current State of the Art and Future Perspectives. <i>Cancers</i> , 2021, 13, 1714.	3.7	14
437	IFN- γ -dependent NK cell activation is essential to metastasis suppression by engineered Salmonella. <i>Nature Communications</i> , 2021, 12, 2537.	12.8	36
438	Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies. <i>Clinical Cancer Research</i> , 2021, 27, 3744-3756.	7.0	69
439	Natural Killer Cells and T Cells in Hepatocellular Carcinoma and Viral Hepatitis: Current Status and Perspectives for Future Immunotherapeutic Approaches. <i>Cells</i> , 2021, 10, 1332.	4.1	24
440	Human stem cell-based models for studying host-pathogen interactions. <i>Cellular Microbiology</i> , 2021, 23, e13335.	2.1	13
441	High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	29

#	ARTICLE	IF	CITATIONS
442	Harnessing Innate Immunity Using Biomaterials for Cancer Immunotherapy. <i>Advanced Materials</i> , 2021, 33, e2007576.	21.0	42
443	Nano-delivery systems focused on tumor microenvironment regulation and biomimetic strategies for treatment of breast cancer metastasis. <i>Journal of Controlled Release</i> , 2021, 333, 374-390.	9.9	40
444	Tumor-associated macrophages in cholangiocarcinoma: complex interplay and potential therapeutic target. <i>EBioMedicine</i> , 2021, 67, 103375.	6.1	33
445	Myricetin protects natural killer cells from arsenite induced DNA damage by attenuating oxidative stress and retaining poly(ADP-Ribose) polymerase 1 activity. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2021, 865, 503337.	1.7	1
446	Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5801.	4.1	182
447	Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs. <i>Cancers</i> , 2021, 13, 2500.	3.7	39
448	Pan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy. <i>British Journal of Cancer</i> , 2021, 125, 422-432.	6.4	59
449	Identification and functional study of novel oligonucleotides: CpG Seq 13 and CpG Seq 19. <i>Immunotherapy</i> , 2021, 13, 571-585.	2.0	0
450	The Role of Sphingolipids in Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6492.	4.1	11
451	Circulating and Tumor-Infiltrating NK Cells From Clear Cell Renal Cell Carcinoma Patients Exhibit a Predominantly Inhibitory Phenotype Characterized by Overexpression of CD85j, CD45, CD48 and PD-1. <i>Frontiers in Immunology</i> , 2021, 12, 681615.	4.8	16
452	Metabolic flexibility determines human NK cell functional fate in the tumor microenvironment. <i>Cell Metabolism</i> , 2021, 33, 1205-1220.e5.	16.2	104
453	Cancer vaccines: An unkept promise?. <i>Drug Discovery Today</i> , 2021, 26, 1347-1352.	6.4	7
454	Adaptive Subsets Limit the Anti-Tumoral NK-Cell Activity in Hepatocellular Carcinoma. <i>Cells</i> , 2021, 10, 1369.	4.1	6
455	Boosting immune system against cancer by resveratrol. <i>Phytotherapy Research</i> , 2021, 35, 5514-5526.	5.8	27
456	The “Magic Bullet” Is Here? Cell-Based Immunotherapies for Hematological Malignancies in the Twilight of the Chemotherapy Era. <i>Cells</i> , 2021, 10, 1511.	4.1	3
457	Emerging nanomaterials for cancer immunotherapy. <i>Exploration of Medicine</i> , 2021, 2, 208-231.	1.5	1
458	Engineered immune cells with nanomaterials to improve adoptive cell therapy. <i>Biomedical Engineering Letters</i> , 2021, 11, 183-195.	4.1	1
459	The Impact of NK Cell-Based Therapeutics for the Treatment of Lung Cancer for Biologics: Targets and Therapy. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 265-277.	3.2	10

#	ARTICLE	IF	CITATIONS
460	A novel endogenous CD16-Expressing Natural Killer Cell for cancer immunotherapy. Biochemistry and Biophysics Reports, 2021, 26, 100935.	1.3	9
461	Nanobiotechnology and Immunotherapy: Two Powerful and Cooperative Allies against Cancer. Cancers, 2021, 13, 3765.	3.7	7
462	EZH2 inhibits NK cell-mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	37
463	Leveraging NKG2D Ligands in Immuno-Oncology. Frontiers in Immunology, 2021, 12, 713158.	4.8	56
464	Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduction and Targeted Therapy, 2021, 6, 263.	17.1	739
465	Instruction of Immunometabolism by Adipose Tissue: Implications for Cancer Progression. Cancers, 2021, 13, 3327.	3.7	4
466	Three-Dimensional Culture Models to Study Innate Anti-Tumor Immune Response: Advantages and Disadvantages. Cancers, 2021, 13, 3417.	3.7	14
467	Cancer immunotherapy: A comprehensive appraisal of its modes of application (Review). Oncology Letters, 2021, 22, 655.	1.8	17
468	Immune Checkpoint Inhibitors in Human Glioma Microenvironment. Frontiers in Immunology, 2021, 12, 679425.	4.8	76
469	Bi-specific and Tri-specific NK Cell Engagers: The New Avenue of Targeted NK Cell Immunotherapy. Molecular Diagnosis and Therapy, 2021, 25, 577-592.	3.8	27
470	Environmental activation of a hypothalamic BDNF-adipocyte IL-15 axis regulates adipose-natural killer cells. Brain, Behavior, and Immunity, 2021, 95, 477-488.	4.1	5
471	High-grade serous ovarian tumor cells modulate NK cell function to create an immune-tolerant microenvironment. Cell Reports, 2021, 36, 109632.	6.4	26
472	Annexin A1 as a Regulator of Immune Response in Cancer. Cells, 2021, 10, 2245.	4.1	42
473	Roles and Regulation of Growth differentiation factor-15 in the Immune and tumor microenvironment. Human Immunology, 2021, 82, 937-944.	2.4	13
474	Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma. International Journal of Oral Science, 2021, 13, 24.	8.6	107
475	Dual-functional super bispecific nano-antibodies derived from monoclonal antibodies potentiate the antitumor effect of innate immune cells. Nano Today, 2021, 39, 101209.	11.9	8
476	Activatable luminescent probes for imaging brain diseases. Nano Today, 2021, 39, 101239.	11.9	9
477	Effect of Conventional Chemotherapies on Natural Killer Cell Activity. Current Cancer Therapy Reviews, 2021, 17, 251-254.	0.3	0

#	ARTICLE	IF	CITATIONS
478	NK Cells in Myeloproliferative Neoplasms (MPN). <i>Cancers</i> , 2021, 13, 4400.	3.7	0
479	Small Extracellular Vesicles and Metastasis—Blame the Messenger. <i>Cancers</i> , 2021, 13, 4380.	3.7	11
480	Advances in Biomimetic Nanoparticles for Targeted Cancer Therapy and Diagnosis. <i>Molecules</i> , 2021, 26, 5052.	3.8	33
481	Specific Blood Cells Derived from Pluripotent Stem Cells: An Emerging Field with Great Potential in Clinical Cell Therapy. <i>Stem Cells International</i> , 2021, 2021, 1-16.	2.5	1
482	Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments. <i>Seminars in Cancer Biology</i> , 2021, 77, 144-166.	9.6	50
483	Natural Killer Cells and Dendritic Cells: Expanding Clinical Relevance in the Non-Small Cell Lung Cancer (NSCLC) Tumor Microenvironment. <i>Cancers</i> , 2021, 13, 4037.	3.7	16
484	Bioinformatics analysis for the biomarkers of the tumor-infiltrating lymphocytes in head and neck squamous cell carcinoma. <i>Translational Cancer Research</i> , 2021, 10, 3716-3725.	1.0	2
485	Current Trends of Immunotherapy in the Treatment of Cutaneous Melanoma: A Review. <i>Dermatology and Therapy</i> , 2021, 11, 1481-1496.	3.0	12
486	Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1267-1288.	1.1	77
487	Immune aspects of hepatocellular carcinoma: From immune markers for early detection to immunotherapy. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1132-1143.	2.0	2
488	Engineered Bifunctional Proteins for Targeted Cancer Therapy: Prospects and Challenges. <i>Advanced Materials</i> , 2021, 33, e2103114.	21.0	6
489	PBX1: a key character of the hallmarks of cancer. <i>Journal of Molecular Medicine</i> , 2021, 99, 1667-1680.	3.9	16
490	Ex Vivo Expanded and Activated Natural Killer Cells Prolong the Overall Survival of Mice with Glioblastoma-like Cell-Derived Tumors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9975.	4.1	10
491	Kill and Clearance in HCC: An Approach Based on NK Cells and Macrophages. <i>Frontiers in Oncology</i> , 2021, 11, 693076.	2.8	2
492	HNRNPC Promotes Proliferation, Metastasis and Predicts Prognosis in Prostate Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 7263-7276.	1.9	15
493	An Alternative Cell Therapy for Cancers: Induced Pluripotent Stem Cell (iPSC)-Derived Natural Killer Cells. <i>Biomedicines</i> , 2021, 9, 1323.	3.2	7
494	Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition. <i>Cell Death and Disease</i> , 2021, 12, 836.	6.3	13
495	Functional NK Cell Activation by Ovalbumin Immunization with a Monophosphoryl Lipid A and Poly I:C Combination Adjuvant Promoted Dendritic Cell Maturation. <i>Vaccines</i> , 2021, 9, 1061.	4.4	5

#	ARTICLE	IF	CITATIONS
496	Ex Vivo Expansion and CRISPR-Cas9 Genome Editing of Primary Human Natural Killer Cells. <i>Current Protocols</i> , 2021, 1, e246.	2.9	2
497	Tumor-Experienced Human NK Cells Express High Levels of PD-L1 and Inhibit CD8+ T Cell Proliferation. <i>Frontiers in Immunology</i> , 2021, 12, 745939.	4.8	22
498	Selenium stimulates the antitumour immunity: Insights to future research. <i>European Journal of Cancer</i> , 2021, 155, 256-267.	2.8	81
499	Characterization of Exosome-Related Gene Risk Model to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Triple-Negative Breast Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 736030.	4.8	20
500	Immunobiology of Melanoma. <i>Clinics in Plastic Surgery</i> , 2021, 48, 561-576.	1.5	5
501	Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 311.	8.6	26
502	Clinical Impact of Natural Killer Group 2D Receptor Expression and That of Its Ligand in Ovarian Carcinomas: A Retrospective Study. <i>Yonsei Medical Journal</i> , 2021, 62, 288.	2.2	5
503	Irradiated Tumor Fibroblasts Avoid Immune Recognition and Retain Immunosuppressive Functions Over Natural Killer Cells. <i>Frontiers in Immunology</i> , 2020, 11, 602530.	4.8	21
504	CAR-NK cell immunotherapy: Development and challenges toward an off-the-shelf product. , 2021, , 213-230.		2
505	Cbl-b Is Upregulated and Plays a Negative Role in Activated Human NK Cells. <i>Journal of Immunology</i> , 2021, 206, 677-685.	0.8	10
506	Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy. <i>Journal of Leukocyte Biology</i> , 2021, 109, 1071-1088.	3.3	25
507	An Improved Method to Produce Clinical-Scale Natural Killer Cells from Human Pluripotent Stem Cells. <i>Methods in Molecular Biology</i> , 2019, 2048, 107-119.	0.9	75
508	The role of NK cell as central communicators in cancer immunity. <i>Advances in Immunology</i> , 2020, 147, 61-88.	2.2	15
509	Nano-herb medicine and PDT induced synergistic immunotherapy for colon cancer treatment. <i>Biomaterials</i> , 2021, 269, 120654.	11.4	60
510	Targeting acute myeloid leukemia stem cells: Current therapies in development and potential strategies with new dimensions. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 152, 102993.	4.4	16
511	Photothermal therapies to improve immune checkpoint blockade for cancer. <i>International Journal of Hyperthermia</i> , 2020, 37, 34-49.	2.5	23
512	Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients. <i>Oncolimmunology</i> , 2021, 10, 1853314.	4.6	24
513	Cancer cells educate natural killer cells to a metastasis-promoting cell state. <i>Journal of Cell Biology</i> , 2020, 219, .	5.2	85

#	ARTICLE	IF	CITATIONS
514	Natural Killer Cells: Critical Effectors During Antibody-mediated Rejection of Solid Organ Allografts. Transplantation, 2021, 105, 284-290.	1.0	13
518	Landscape of natural killer cell activity in head and neck squamous cell carcinoma. , 2020, 8, e001523.		36
519	Targetable mechanisms driving immunoevasion of persistent senescent cells link chemotherapy-resistant cancer to aging. JCI Insight, 2019, 4, .	5.0	90
520	Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells. Journal of Clinical Investigation, 2019, 129, 2094-2106.	8.2	225
521	CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment. Journal of Clinical Investigation, 2020, 130, 1185-1198.	8.2	139
522	T lymphocytes against solid malignancies: winning ways to defeat tumours. Cell Stress, 2018, 2, 200-212.	3.2	22
523	LTX-315 sequentially promotes lymphocyte-independent and lymphocyte-dependent antitumor effects. Cell Stress, 2019, 3, 348-360.	3.2	19
524	Clinical and transcriptional signatures of human CD204 reveal an applicable marker for the protumor phenotype of tumor-associated macrophages in breast cancer. Aging, 2019, 11, 10883-10901.	3.1	8
525	The anti-tumor role of NK cells <i>in vivo</i> pre-activated and re-stimulated by interleukins in acute lymphoblastic leukemia. Oncotarget, 2016, 7, 79187-79202.	1.8	17
526	Peritoneal NK cells are responsive to IL-15 and percentages are correlated with outcome in advanced ovarian cancer patients. Oncotarget, 2018, 9, 34810-34820.	1.8	44
527	TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic. Oncotarget, 2020, 11, 3753-3769.	1.8	18
528	Lectin-like transcript 1 as a natural killer cell-mediated immunotherapeutic target for triple negative breast cancer and prostate cancer. Journal of Cancer Metastasis and Treatment, 2019, 2019, .	0.8	2
529	Cell-mediated immune resistance in cancer. , 2020, 3, 232-251.		9
530	Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers. Cancer Biology and Medicine, 2020, 17, 1026-1038.	3.0	26
531	<p>Dinutuximab Synergistically Enhances the Cytotoxicity of Natural Killer Cells to Retinoblastoma Through the Perforin-Granzyme B Pathway<p>. OncoTargets and Therapy, 2020, Volume 13, 3903-3920.	2.0	7
532	Enhanced NK-92 Cytotoxicity by CRISPR Genome Engineering Using Cas9 Ribonucleoproteins. Frontiers in Immunology, 2020, 11, 1008.	4.8	57
533	Genetic Engineering of Natural Killer Cells for Enhanced Antitumor Function. Frontiers in Immunology, 2020, 11, 607131.	4.8	16
534	ADOPTIVE CELL THERAPY: CURRENT ADVANCES. South Russian Journal of Cancer, 2020, 1, 43-59.	0.6	5

#	ARTICLE	IF	CITATIONS
535	Ambiguous roles and potential therapeutic strategies of innate lymphoid cells in different types of tumor (Review). <i>Oncology Letters</i> , 2020, 20, 1513-1525.	1.8	7
536	Differential Fuel Requirements of Human NK Cells and Human CD8 T Cells: Glutamine Regulates Glucose Uptake in Strongly Activated CD8 T Cells. <i>ImmunoHorizons</i> , 2020, 4, 231-244.	1.8	11
537	NK Cell-Based Immunotherapies in Cancer. <i>Immune Network</i> , 2020, 20, e14.	3.6	79
538	Remarkably Low<i>KIR</i>and<i>HLA</i>Diversity in Amerindians Reveals Signatures of Strong Purifying Selection Shaping the Centromeric<i>KIR</i>Region. <i>Molecular Biology and Evolution</i> , 2022, 39, .	8.9	8
539	The Prognostic and Immunological Value of Guanylate-Binding Proteins in Lower-Grade Glioma: Potential Markers or Not?. <i>Frontiers in Genetics</i> , 2021, 12, 651348.	2.3	1
540	NK Cell-Based Immunotherapy and Therapeutic Perspective in Gliomas. <i>Frontiers in Oncology</i> , 2021, 11, 751183.	2.8	10
541	Nanobodyâ€Engineered Natural Killer Cell Conjugates for Solid Tumor Adoptive Immunotherapy. <i>Small</i> , 2021, 17, e2103463.	10.0	20
542	Cytokine-induced natural killer cell training is dependent on cellular metabolism and is defective in obesity. <i>Blood Advances</i> , 2021, 5, 4447-4455.	5.2	16
543	Overview of Immune System. , 2016, , 113-142.		0
544	Natural Killer Cells in Hepatocellular Carcinoma: Anti-Tumor Effect and Therapeutic Potential. , 2017, , 19-38.		0
545	Ubiquitin and ubiquitin-like modifiers modulate NK cell-mediated recognition and killing of damaged cells. <i>AIMS Allergy and Immunology</i> , 2017, 1, 164-180.	0.5	0
548	Immunomodulation of NK Cell Activity. <i>Methods in Molecular Biology</i> , 2020, 2097, 125-136.	0.9	1
549	Isolation and Characterization of Innate Lymphoid Cells within the Murine Tumor Microenvironment. <i>Methods in Molecular Biology</i> , 2020, 2121, 153-164.	0.9	2
550	Natural killer cells and immunotherapy based on monoclonal antibodies. <i>Biomedical Reviews</i> , 2021, 31, 61.	0.6	0
551	Treatment options for localised renal cell carcinoma of the transplanted kidney. <i>World Journal of Transplantation</i> , 2020, 10, 147-161.	1.6	4
553	Ferroptosis regulators, especially SQLE, play an important role in prognosis, progression and immune environment of breast cancer. <i>BMC Cancer</i> , 2021, 21, 1160.	2.6	15
554	An 8-week randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of red Platycodon grandiflorus root extract on enhancement of immune function. <i>Phytomedicine</i> , 2021, 93, 153811.	5.3	1
556	Cell-based immunotherapy in gynecologic malignancies. <i>Current Opinion in Obstetrics and Gynecology</i> , 2021, 33, 13-18.	2.0	1

#	ARTICLE	IF	CITATIONS
557	Treatment of Acute Myeloid Leukemia: A Concise Overview. Abasyn Journal of Life Sciences, 2020, , 111-128.	0.1	0
558	The evolving role of immune cells in prostate cancer. Cancer Letters, 2022, 525, 9-21.	7.2	34
559	Metformin promotes anticancer activity of NK cells in a p38 MAPK dependent manner. Oncoimmunology, 2021, 10, 1995999.	4.6	22
560	PHENOTYPIC HETEROGENEITY OF NEUTROPHILS: NEW ANTIMICROBIC CHARACTERISTICS AND DIAGNOSTIC TECHNOLOGIES. Gematologiya I Transfuziologiya, 2019, 64, 211-221.	0.6	6
562	Immunohistochemical characterization of immune cell infiltrate in gastrointestinal stromal tumor and its prognostic correlation. Egyptian Journal of Pathology, 2020, 40, 229.	0.0	1
563	An Intellectual History of Multilevel Selection: Reformulation and Resuscitation. , 2020, , 41-70.		0
564	Identification of Methylation Immune Subtypes and Establishment of a Prognostic Signature for Gliomas Using Immune-Related Genes. Frontiers in Immunology, 2021, 12, 737650.	4.8	4
565	The Immune Infiltration in HNSCC and Its Clinical Value: A Comprehensive Study Based on the TCGA and GEO Databases. Computational and Mathematical Methods in Medicine, 2021, 2021, 1-11.	1.3	9
566	Gender Differences in Urothelial Bladder Cancer: Effects of Natural Killer Lymphocyte Immunity. Journal of Clinical Medicine, 2021, 10, 5163.	2.4	6
567	Tumor Marker B7-H6 Bound to the Coiled Coil Peptide-Polymer Conjugate Enables Targeted Therapy by Activating Human Natural Killer Cells. Biomedicines, 2021, 9, 1597.	3.2	2
570	The application of the natural killer cells, macrophages and dendritic cells in treating various types of cancer. ChemistrySelect, 2022, 7, 833-866.	1.5	0
571	Focal adhesion kinase (FAK) deficiency in mononuclear phagocytes alters murine breast tumor progression. American Journal of Cancer Research, 2018, 8, 675-687.	1.4	3
572	Blocking LLT1 (CLEC2D, OCIL)-NKR1A (CD161) interaction enhances natural killer cell-mediated lysis of triple-negative breast cancer cells. American Journal of Cancer Research, 2018, 8, 1050-1063.	1.4	18
573	CAR-armed cell therapy for gliomas. American Journal of Cancer Research, 2019, 9, 2554-2566.	1.4	2
574	Changes in and effects of Kupffer cells on residual tumor after cryoablation in rabbit hepatic VX2 tumor. International Journal of Clinical and Experimental Pathology, 2021, 14, 75-85.	0.5	1
575	Natural killer cells: of-the-shelf cytotherapy for cancer immunosurveillance. American Journal of Cancer Research, 2021, 11, 1770-1791.	1.4	3
576	The Interplay between Salmonella and Intestinal Innate Immune Cells in Chickens. Pathogens, 2021, 10, 1512.	2.8	16
577	Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges. Molecular Therapy - Oncolytics, 2022, 24, 26-42.	4.4	26

#	ARTICLE	IF	CITATIONS
578	Targeted integration of EpCAM-specific CAR in human induced pluripotent stem cells and their differentiation into NK cells. <i>Stem Cell Research and Therapy</i> , 2021, 12, 580.	5.5	7
579	Antioxidant/Pro-oxidant, Anti-inflammatory, and Immunomodulatory Effects of Thymoquinone in Cancer Prevention and Treatment. , 2022, , 1-14.		0
580	The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112516.	5.6	38
581	Innate tumor killers in colorectal cancer. <i>Cancer Letters</i> , 2022, 527, 115-126.	7.2	11
582	NK Cell Anti-Tumor Surveillance in a Myeloid Cell-Shaped Environment. <i>Frontiers in Immunology</i> , 2021, 12, 787116.	4.8	16
583	The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems. <i>Frontiers in Oncology</i> , 2021, 11, 704999.	2.8	8
584	Mesenchymal Stem Cell Immunomodulation: A Novel Intervention Mechanism in Cardiovascular Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 742088.	3.7	8
585	A spatial and cellular distribution of rabies virus infection in the mouse brain revealed by fMOST and singleâ€cell RNA sequencing. <i>Clinical and Translational Medicine</i> , 2022, 12, e700.	4.0	6
586	Lirilumab and Avelumab Enhance Anti-HPV+ Cervical Cancer Activity of Natural Killer Cells via Vav1-Dependent NF-ÎB Disinhibition. <i>Frontiers in Oncology</i> , 2022, 12, 747482.	2.8	3
587	Impact on NK cell functions of acute versus chronic exposure to extracellular vesicleâ€associated MICA: Dual role in cancer immunosurveillance. <i>Journal of Extracellular Vesicles</i> , 2022, 11, e12176.	12.2	22
588	Specific immune status in Parkinsonâ€™s disease at different ages of onset. <i>Npj Parkinson's Disease</i> , 2022, 8, 5.	5.3	26
589	NK cells in the brain: implications for brain tumor development and therapy. <i>Trends in Molecular Medicine</i> , 2022, 28, 194-209.	6.7	10
590	The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy. <i>Cellular and Molecular Immunology</i> , 2022, 19, 192-209.	10.5	51
591	iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting. <i>Frontiers in Immunology</i> , 2022, 13, 841107.	4.8	42
592	Cell-intrinsic view of the aryl hydrocarbon receptor in tumor immunity. <i>Trends in Immunology</i> , 2022, 43, 245-258.	6.8	16
593	Adoptive cell therapies in thoracic malignancies. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2077-2098.	4.2	4
594	Circulating Tumor Cells: Does Ion Transport Contribute to Intravascular Survival, Adhesion, Extravasation, and Metastatic Organotropism?. <i>Reviews of Physiology, Biochemistry and Pharmacology</i> , 2021, , 1.	1.6	2
595	CRISPR Screen to Identify Factors that Render Tumor Cells Sensitive or Resistant to Killing by NK Cells. <i>Methods in Molecular Biology</i> , 2022, 2463, 269-288.	0.9	0

#	ARTICLE	IF	CITATIONS
596	Natural killer cell-based strategies for immunotherapy of cancer. <i>Advances in Protein Chemistry and Structural Biology</i> , 2022, 129, 91-133.	2.3	6
597	Role of NK Cells in Tumor Progression. <i>Experientia Supplementum</i> (2012), 2022, 113, 169-187.	0.9	1
598	Identification of lncRNA Signature of Tumor-Infiltrating T Lymphocytes With Potential Implications for Prognosis and Chemotherapy of Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Pharmacology</i> , 2021, 12, 795205.	3.5	7
599	Fatty Acid Metabolism and Cancer Immunotherapy. <i>Current Oncology Reports</i> , 2022, 24, 659-670.	4.0	23
600	Cell Type-Specific Roles of STAT3 Signaling in the Pathogenesis and Progression of K-ras Mutant Lung Adenocarcinoma. <i>Cancers</i> , 2022, 14, 1785.	3.7	3
601	Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer. <i>Clinical and Experimental Immunology</i> , 2022, 209, 22-32.	2.6	14
602	The Role of Extracellular Vesicles in Systemic Lupus Erythematosus. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 835566.	3.7	5
603	Biology and Clinical Relevance of HCMV-Associated Adaptive NK Cells. <i>Frontiers in Immunology</i> , 2022, 13, 830396.	4.8	4
604	Moesin: A novel receptor on NK lymphocytes binds to TOMM40 on K562 leukemia cells initiating cytolysis. <i>Human Immunology</i> , 2022, 83, 418-427.	2.4	2
605	The changing role of natural killer cells in cancer metastasis. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	36
606	Biomimetic and Materials-Potentiated Cell Engineering for Cancer Immunotherapy. <i>Pharmaceutics</i> , 2022, 14, 734.	4.5	1
607	Targeting the RNA m6A modification for cancer immunotherapy. <i>Molecular Cancer</i> , 2022, 21, 76.	19.2	78
608	STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer. <i>OncolImmunology</i> , 2022, 11, 2054105.	4.6	27
609	IDO1 can impair NK cells function against non-small cell lung cancer by downregulation of NKG2D Ligand via ADAM10. <i>Pharmacological Research</i> , 2022, 177, 106132.	7.1	11
610	Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?. <i>Drug Design, Development and Therapy</i> , 2022, Volume 16, 951-972.	4.3	4
611	Innate lymphoid cells in colorectal cancer. <i>Scandinavian Journal of Immunology</i> , 2022, 95, e13156.	2.7	10
612	Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas. <i>JCI Insight</i> , 2022, 7, .	5.0	14
613	Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies. <i>Frontiers in Immunology</i> , 2022, 13, 847008.	4.8	12

#	ARTICLE	IF	CITATIONS
614	A chimeric switch-receptor PD1-DAP10-41BB augments NK92-cell activation and killing for human lung Cancer H1299 Cell. <i>Biochemical and Biophysical Research Communications</i> , 2022, 600, 94-100.	2.1	2
615	Ovarian Cancer Ascites Inhibits Transcriptional Activation of NK Cells Partly through CA125. <i>Journal of Immunology</i> , 2022, 208, 2227-2238.	0.8	6
616	The interplay of thyroid hormones and the immune system “where we stand and why we need to know about it. <i>European Journal of Endocrinology</i> , 2022, 186, R65-R77.	3.7	29
617	TM4SF5-mediated liver malignancy involves NK cell exhaustion-like phenotypes. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 1.	5.4	13
618	Prospects for Development of Induced Pluripotent Stem Cell-Derived CAR-Targeted Immunotherapies. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2022, 70, 2.	2.3	13
619	CAR-NK Cells: From Natural Basis to Design for Kill. <i>Frontiers in Immunology</i> , 2021, 12, 707542.	4.8	50
620	NK cell upraise in the dark world of cancer stem cells. <i>Cancer Cell International</i> , 2021, 21, 682.	4.1	9
621	CRISPR Screens to Identify Regulators of Tumor Immunity. <i>Annual Review of Cancer Biology</i> , 2022, 6, 103-122.	4.5	5
622	Natural killer cells in liver transplantation: Can we harness the power of the immune checkpoint to promote tolerance?. <i>Clinical and Translational Science</i> , 2022, 15, 1091-1103.	3.1	4
623	Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review. <i>Frontiers in Immunology</i> , 2021, 12, 775761.	4.8	45
624	Cell-based immunotherapies in gynecologic cancers. <i>Current Opinion in Obstetrics and Gynecology</i> , 2022, 34, 10-14.	2.0	0
625	Biological therapies in patients with liver disease: are they really lifesavers?. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 473-490.	3.1	0
626	Challenges and Recent Advances in NK Cell-Targeted Immunotherapies in Solid Tumors. <i>International Journal of Molecular Sciences</i> , 2022, 23, 164.	4.1	14
627	NK Cells and Innate-Like T Cells After Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2021, 12, 794077.	4.8	7
628	Prognostic Role of Circulating Tumor Cells in the Pulmonary Vein, Peripheral Blood, and Bone Marrow in Resectable Non-Small Cell Lung Cancer. <i>Journal of Chest Surgery</i> , 2022, , .	0.5	0
629	The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2731-2742.	4.2	6
630	Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis. <i>Cell</i> , 2022, 185, 1521-1538.e18.	28.9	63
631	The tricks for fighting against cancer using CAR NK cells: A review. <i>Molecular and Cellular Probes</i> , 2022, 63, 101817.	2.1	5

#	ARTICLE	IF	CITATIONS
672	Immune System Abnormalities in Schizophrenia: An Integrative View and Translational Perspectives. <i>Frontiers in Psychiatry</i> , 2022, 13, 880568.	2.6	43
673	Upregulation of Ferroptosis-Related Fanconi Anemia Group D2 is a Poor Prognostic Factor and an Indicator of Tumor Immune Cell Infiltration in Lung Adenocarcinoma. <i>Frontiers in Genetics</i> , 2022, 13, .	2.3	5
674	Identification of Five m6A-Related lncRNA Genes as Prognostic Markers for Endometrial Cancer Based on TCGA Database. <i>Journal of Immunology Research</i> , 2022, 2022, 1-13.	2.2	5
675	Transcriptomic Analysis of the Spleen of Different Chicken Breeds Revealed the Differential Resistance of <i>Salmonella Typhimurium</i> . <i>Genes</i> , 2022, 13, 811.	2.4	5
676	Abnormal immune function of MDSC and NK cells from chronic phase CML patients restores with tyrosine kinase inhibitors. <i>International Immunopharmacology</i> , 2022, 109, 108821.	3.8	3
677	Advances of research of Fc-fusion protein that activate NK cells for tumor immunotherapy. <i>International Immunopharmacology</i> , 2022, 109, 108783.	3.8	8
678	Overview: Themes in Innate Lymphoid Cell Biology. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1365, 1-6.	1.6	0
679	NK Cells and ILC1s in Cancer Biology. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1365, 41-55.	1.6	2
680	Generation and clinical potential of functional T lymphocytes from gene-edited pluripotent stem cells. <i>Experimental Hematology and Oncology</i> , 2022, 11, 27.	5.0	6
681	Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells. , 2022, 10, e004693.		29
682	NKG2C+ NK Cells for Immunotherapy of Glioblastoma Multiforme. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5857.	4.1	9
683	Molecular Basis and Role of Siglec-7 Ligand Expression on Chronic Lymphocytic Leukemia B Cells. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	14
684	Integrative Pan-Cancer Analysis Confirmed that FCGR3A is a Candidate Biomarker Associated With Tumor Immunity. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	10
685	Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	7
686	Natural killer cells and acute myeloid leukemia: promises and challenges. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2849-2867.	4.2	5
687	Harnessing Unconventional T Cells and Innate Lymphoid Cells to Prevent and Treat Hematological Malignancies: Prospects for New Immunotherapy. <i>Biomolecules</i> , 2022, 12, 754.	4.0	5
688	Nanotechnology for Enhanced Cytoplasmic and Organelle Delivery of Bioactive Molecules to Immune Cells. <i>Pharmaceutical Research</i> , 2022, 39, 1065-1083.	3.5	3
689	The establishment of polypeptide PSMA-targeted chimeric antigen receptor-engineered natural killer cells for castration-resistant prostate cancer and the induction of ferroptosis-related cell death. <i>Cancer Communications</i> , 2022, 42, 768-783.	9.2	12

#	ARTICLE	IF	CITATIONS
690	Role of the ITAM-Bearing Receptors Expressed by Natural Killer Cells in Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	8
691	Generation of universal natural killer cells from a cryopreserved cord blood mononuclear cellâ€derived induced pluripotent stem cell library. <i>FEBS Open Bio</i> , 0, , .	2.3	4
692	Breast Cancer Metastasis: Mechanisms and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6806.	4.1	74
693	Tyrosinase-Mediated Synthesis of Nanobodyâ€Cell Conjugates. <i>ACS Central Science</i> , 2022, 8, 955-962.	11.3	10
694	Overcome tumor relapse in CAR T cell therapy. <i>Clinical and Translational Oncology</i> , 0, , .	2.4	2
695	Thrombospondin-2 acts as a bridge between tumor extracellular matrix and immune infiltration in pancreatic and stomach adenocarcinomas: an integrative pan-cancer analysis. <i>Cancer Cell International</i> , 2022, 22, .	4.1	10
696	The prognostic role of NKG2A expression for patients with chronic myeloid leukemia after treatment discontinuation. <i>Leukemia and Lymphoma</i> , 0, , 1-11.	1.3	3
697	Fingolimod-Conjugated Charge-Altering Releasable Transporters Efficiently and Specifically Deliver mRNA to Lymphocytes In Vivo and In Vitro. <i>Biomacromolecules</i> , 2022, 23, 2976-2988.	5.4	5
698	Innovative cancer nanomedicine based on immunology, gene editing, intracellular trafficking control. <i>Journal of Controlled Release</i> , 2022, 348, 357-369.	9.9	3
699	Sintilimab Plus Autologous NK Cells as Second-Line Treatment for Advanced Non-Small-Cell Lung Cancer Previous Treated with Platinum-Containing Chemotherapy. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
700	Nanotechnology-Based siRNA Delivery Systems to Overcome Tumor Immune Evasion in Cancer Immunotherapy. <i>Pharmaceutics</i> , 2022, 14, 1344.	4.5	8
701	Exosomal microRNAs (exoMIRs): micromolecules with macro impact in oral cancer. <i>3 Biotech</i> , 2022, 12, .	2.2	22
702	A Novel Prognostic Signature Revealed the Interaction of Immune Cells in Tumor Microenvironment Based on Single-Cell RNA Sequencing for Lung Adenocarcinoma. <i>Journal of Immunology Research</i> , 2022, 2022, 1-26.	2.2	3
703	TA-MSCs, TA-MSCs-EVs, MIF: their crosstalk in immunosuppressive tumor microenvironment. <i>Journal of Translational Medicine</i> , 2022, 20, .	4.4	2
704	NAD ⁺ salvage governs mitochondrial metabolism, invigorating natural killer cell antitumor immunity. <i>Hepatology</i> , 2023, 78, 468-485.	7.3	12
705	NK Cells and Other Cytotoxic Innate Lymphocytes in Colorectal Cancer Progression and Metastasis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7859.	4.1	10
706	Cellâ€Cell Interactions Drive Metastasis of Circulating Tumor Microemboli. <i>Cancer Research</i> , 2022, 82, 2661-2671.	0.9	11
707	Host-Related Factors as Targetable Drivers of Immunotherapy Response in Non-Small Cell Lung Cancer Patients. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	6

#	ARTICLE	IF	CITATIONS
708	Immune Evasion of Hepatoma Cancer Stem-Like Cells from Natural Killer Cells. <i>Annals of Surgical Oncology</i> , 2022, 29, 7423-7433.	1.5	4
709	GAS6/TAM signaling pathway controls MICA expression in multiple myeloma cells. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	2
710	Identification of Nine M6A-Related Long Noncoding RNAs as Prognostic Signatures Associated with Oxidative Stress in Oral Cancer Based on Data from The Cancer Genome Atlas. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-18.	4.0	4
711	A tumor microenvironment gene setâ€œBased prognostic signature for non-small-cell lung cancer. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	3.5	2
712	Harnessing natural killer cells to develop nextâ€œgeneration cellular immunotherapy. <i>Chronic Diseases and Translational Medicine</i> , 2022, 8, 245-255.	1.2	0
713	Innate lymphoid cells in early tumor development. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	6
714	A bibliometric and scientific knowledge-map study of the chimeric antigen receptor (CAR) natural killer (NK) cell-related research from 2010 to 2022. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	3
715	Advanced Cell Therapies for Glioblastoma. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	7
716	Minimally invasive detection of cancer using metabolic changes in tumor-associated natural killer cells with Oncoimmune probes. <i>Nature Communications</i> , 2022, 13, .	12.8	7
717	GARP-mediated active TGF-Î²1 induces bone marrow NK cell dysfunction in AML patients with early relapse postâ€œallo-HSCT. <i>Blood</i> , 2022, 140, 2788-2804.	1.4	15
718	Unleashing Anti-Tumor Activity of Natural Killer Cells Via Modulation of Immune Checkpoints Receptors and Molecules. , 0, 8, 463-471.		1
719	Underlying mechanisms of evasion from NK cells as rationale for improvement of NK cell-based immunotherapies. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	12
720	Evaluation of the Influence of Biological Factors during the Course of Treatment in Patients with Ovarian Cancer. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 10516.	2.6	2
721	CD200 ectodomain shedding into the tumor microenvironment leads to NK cell dysfunction and apoptosis. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	13
722	NK cell immunometabolism as target for liver cancer therapy. <i>International Immunopharmacology</i> , 2022, 112, 109193.	3.8	3
723	Mechanisms of Action of Radiotherapy and Immunotherapy in Lung Cancer: Implications for Clinical Practice. <i>Medical Radiology</i> , 2022, , .	0.1	1
724	Antioxidant/Pro-oxidant, Anti-inflammatory, and Immunomodulatory Effects of Thymoquinone in Cancer Prevention and Treatment. , 2022, , 547-560.		0
725	Synthetic-Based Tumor-Infiltrating Lymphocytes (TILs) in Adoptive Cell Therapies. , 2022, , 1-27.		0

#	ARTICLE	IF	CITATIONS
726	The Interface of Cancer, Their Microenvironment and Nanotechnology. <i>Oncologie</i> , 2022, 24, 371-411.	0.7	2
727	Enhancing Natural Killer Cell-Mediated Cancer Immunotherapy by the Biological Macromolecule <i>Nocardia rubra</i> Cell-Wall Skeleton. <i>Pathology and Oncology Research</i> , 0, 28, .	1.9	4
728	Circulating tumor cell-blood cell crosstalk: Biology and clinical relevance. <i>Cell Reports</i> , 2022, 40, 111298.	6.4	35
729	Multifaceted characterization of the biological and transcriptomic signatures of natural killer cells derived from cord blood and placental blood. <i>Cancer Cell International</i> , 2022, 22, .	4.1	4
730	N-cadherin protects oral cancer cells from NK cell killing in the circulation by inducing NK cell functional exhaustion via the KLRG1 receptor. , 2022, 10, e005061.		3
731	The soldiers needed to be awakened: Tumor-infiltrating immune cells. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	4
732	Altered distribution and function of NK-cell subsets lead to impaired tumor surveillance in JAK2V617F myeloproliferative neoplasms. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	1
733	A novel membrane-bound interleukin-2 promotes NK-92 cell persistence and anti-tumor activity. <i>OncolImmunology</i> , 2022, 11, .	4.6	4
734	Downregulation of SEPTIN5 inhibits prostate cancer progression by increasing CD8 ⁺ T cell infiltration. <i>International Journal of Biological Sciences</i> , 2022, 18, 6035-6051.	6.4	5
735	Exosomal Communication Between the Tumor Microenvironment and Innate Immunity and Its Therapeutic Application. <i>Immune Network</i> , 2022, 22, .	3.6	7
736	Multifunctional NK Cellâ€‘Engaging Antibodies Targeting EGFR and NKp30 Elicit Efficient Tumor Cell Killing and Proinflammatory Cytokine Release. <i>Journal of Immunology</i> , 2022, 209, 1724-1735.	0.8	15
737	Colorectal Cancer and Purinergic Signalling: An Overview. <i>Cancers</i> , 2022, 14, 4887.	3.7	6
738	KIR-HLA gene diversities and susceptibility to lung cancer. <i>Scientific Reports</i> , 2022, 12, .	3.3	5
739	Tissueâ€‘resident CD69 ⁺ CXCR6 ⁺ Natural Killer cells with exhausted phenotype accumulate in human nonâ€‘small cell lung cancer. <i>European Journal of Immunology</i> , 2022, 52, 1993-2005.	2.9	3
740	Targeting EndocytosisÂ and Cell CommunicationsÂ in the Tumor Immune Microenvironment. <i>Cell Communication and Signaling</i> , 2022, 20, .	6.5	3
741	Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation. <i>Advanced Science</i> , 2022, 9, .	11.2	20
742	Impaired intratumoral natural killer cell function in head and neck carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	6
743	Cytometric analysis reveals an association between allergen-responsive natural killer cells and human peanut allergy. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	6

#	ARTICLE	IF	CITATIONS
744	Cell cycle associated miRNAs as target and therapeutics in lung cancer treatment. Heliyon, 2022, 8, e11081.	3.2	8
745	Next Generation Immuno-Oncology Strategies: Unleashing NK Cells Activity. Cells, 2022, 11, 3147.	4.1	3
747	Portal vein tumor thrombosis in hepatocellular carcinoma: molecular mechanism and therapy. Clinical and Experimental Metastasis, 2023, 40, 5-32.	3.3	5
748	Physiology of chemokines in the cancer microenvironment. American Journal of Physiology - Cell Physiology, 2023, 324, C167-C182.	4.6	10
749	Helper innate lymphoid cells as cell therapy for cancer. Immunology, 2023, 168, 569-579.	4.4	2
750	Immunotherapy in gynecologic malignancies. , 2023, , 506-520.e7.		0
751	Innate lymphoid cells: potential targets for cancer therapeutics. Trends in Cancer, 2023, 9, 158-171.	7.4	1
752	Current and Future Perspectives for Chimeric Antigen Receptor T Cells Development in Poland. Biomedicines, 2022, 10, 2912.	3.2	2
753	ZHX2 in health and disease. Frontiers in Oncology, 0, 12, .	2.8	4
754	Natural Killer Cells: A Promising Kit in the Adoptive Cell Therapy Toolbox. Cancers, 2022, 14, 5657.	3.7	4
755	Designing Cancer Immunotherapies That Engage T Cells and NK Cells. Annual Review of Immunology, 2023, 41, 17-38.	21.8	30
756	The prevention of disease relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia. Frontiers in Oncology, 0, 12, .	2.8	3
757	Overcoming the challenges in translational development of natural killer cell therapeutics: An opinion paper. Frontiers in Oncology, 0, 12, .	2.8	0
758	Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy. Frontiers in Immunology, 0, 13, .	4.8	4
759	A Novel Immune Gene-Related Prognostic Score Predicts Survival and Immunotherapy Response in Glioma. Medicina (Lithuania), 2023, 59, 23.	2.0	1
761	Adoptive Cell Transfer for Solid Tumors. , 2023, , .		1
762	Reactivation of natural killer cells with monoclonal antibodies in the microenvironment of malignant neoplasms. Journal of Cancer Research and Clinical Oncology, 0, , .	2.5	1
765	Manipulating NK cellular therapy from cancer to invasive fungal infection: promises and challenges. Frontiers in Immunology, 0, 13, .	4.8	0

#	ARTICLE	IF	CITATIONS
766	Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	12
767	Selenadiazole derivative-loaded metal azolate frameworks facilitate NK cell immunotherapy by sensitizing tumor cells and shaping immuno-suppressive microenvironments. <i>Biomaterials Science</i> , 2023, 11, 1517-1529.	5.4	3
768	Dendritic cells and natural killer cells: The road to a successful oncolytic virotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
769	Natural Killer Cells for Cancer Immunotherapy: Opportunities and Challenges. , 0, , .		0
770	Nanotherapy: New Approach for Impeding Hepatic Cancer Microenvironment via Targeting Multiple Molecular Pathways. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 4261-4274.	1.2	0
771	Janus kinase inhibitors alter NK cell phenotypes and inhibit their antitumour capacity. <i>Rheumatology</i> , 2023, 62, 2855-2863.	1.9	5
772	Cancer immunotherapy via nucleic acid aptamers. , 2023, , 317-346.		0
773	Combination of NK cell immunotherapy with chemotherapy and radiation enhances NK cell therapy and provides improved prognosis in cancer patients and in humanized BLT mouse model system. , 2023, , 301-320.		1
774	NK cell education: Physiological and pathological influences. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	9
775	Long Non-Coding RNAs as Novel Targets for Phytochemicals to Cease Cancer Metastasis. <i>Molecules</i> , 2023, 28, 987.	3.8	3
776	FHL1 as a novel prognostic biomarker and correlation with immune infiltration levels in lung adenocarcinoma. <i>Immunotherapy</i> , 2023, 15, 235-252.	2.0	3
777	Spontaneous Regression of Swine Melanoma: The Role of Tumour-infiltrating T and NK Cells. <i>Anticancer Research</i> , 2023, 43, 631-638.	1.1	0
778	Identification and Validation of Ferroptosis-Related Subtypes and a Predictive Signature in Hepatocellular Carcinoma. <i>Pharmacogenomics and Personalized Medicine</i> , 0, Volume 16, 39-58.	0.7	1
779	Natural killer cells in the treatment of glioblastoma: Diverse antitumor functions and potential clinical applications. , 2023, , 335-367.		1
780	Umbilical Cord Blood Transplantation: Connecting Its Origin to Its Future. <i>Stem Cells Translational Medicine</i> , 2023, 12, 55-71.	3.3	4
781	Heterogeneity of Cholangiocarcinoma Immune Biology. <i>Cells</i> , 2023, 12, 846.	4.1	5
782	The potential role of m6A modifications on immune cells and immunotherapy. <i>Biomedicine and Pharmacotherapy</i> , 2023, 160, 114343.	5.6	5
783	Natural Killer Cell-Based Immunotherapy against Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2111.	4.1	4

#	ARTICLE	IF	CITATIONS
784	An Overview: Genetic Tumor Markers for Early Detection and Current Gene Therapy Strategies. <i>Cancer Informatics</i> , 2023, 22, 117693512211507.	1.9	0
785	Role of natural killer and B cell interaction in inducing pathogen specific immune responses. <i>International Reviews of Immunology</i> , 2023, 42, 304-322.	3.3	1
786	Myelodysplastic Syndrome associated TET2 mutations affect NK cell function and genome methylation. <i>Nature Communications</i> , 2023, 14, .	12.8	7
788	Acid-switchable nanoparticles induce self-adaptive aggregation for enhancing antitumor immunity of natural killer cells. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 3093-3105.	12.0	1
789	Identification of Prognostic Aging-Related Genes Associated with Immune Cell Infiltration in Glioblastoma. <i>Journal of Oncology</i> , 2023, 2023, 1-13.	1.3	0
790	Potential value of efficacy prediction and treatment of <scp>natural killer</scp> cells in extensive stage small cell lung cancer. <i>Thoracic Cancer</i> , 2023, 14, 864-872.	1.9	1
791	The Role of Different Immunocompetent Cell Populations in the Pathogenesis of Head and Neck Cancerâ€™Regulatory Mechanisms of Pro- and Anti-Cancer Activity and Their Impact on Immunotherapy. <i>Cancers</i> , 2023, 15, 1642.	3.7	4
792	Cannabinoid Receptor 1 Agonist ACEA and Cannabinoid Receptor 2 Agonist GW833972A Attenuates Cell-Mediated Immunity by Different Biological Mechanisms. <i>Cells</i> , 2023, 12, 848.	4.1	1
793	The SIX1/LDHA Axis Promotes Lactate Accumulation and Leads to NK Cell Dysfunction in Pancreatic Cancer. <i>Journal of Immunology Research</i> , 2023, 2023, 1-21.	2.2	1
794	Review on the health-promoting effect of adequate selenium status. <i>Frontiers in Nutrition</i> , 0, 10, .	3.7	12
795	Changes in Tumor Immune Microenvironment after Radiotherapy Resistance in Colorectal Cancer: A Narrative Review. <i>Oncology Research and Treatment</i> , 2023, 46, 177-191.	1.2	0
796	Peripheral Mononuclear Cells Surface Markers Evaluation in Different Stages of Hepatocellular Carcinoma; in a Trial for Early and Accurate Diagnosis in Patients with Post-Hepatitis Liver Cirrhosis and Unremarkable Raised AFP. <i>International Journal of General Medicine</i> , 0, Volume 16, 1047-1058.	1.8	0
797	Tumors evade immune cytotoxicity by altering the surface topology of NK cells. <i>Nature Immunology</i> , 2023, 24, 802-813.	14.5	17
798	Natural killer cells suppress human cutaneous squamous cell carcinoma cancer cell survival and tumor growth. <i>Molecular Carcinogenesis</i> , 0, , .	2.7	1
800	Extracellular vesicles in carcinoma microenvironment. <i>Biochemical Society Transactions</i> , 0, , .	3.4	1
802	IL17RB and IL17REL Expression Are Associated with Improved Prognosis in HPV-Infected Head and Neck Squamous Cell Carcinomas. <i>Pathogens</i> , 2023, 12, 572.	2.8	0
803	Regulative Roles of Metabolic Plasticity Caused by Mitochondrial Oxidative Phosphorylation and Glycolysis on the Initiation and Progression of Tumorigenesis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7076.	4.1	3
804	p35 is a Crucial Player in NK-cell Cytotoxicity and TGFÎ²-mediated NK-cell Dysfunction. <i>Cancer Research Communications</i> , 2023, 3, 793-806.	1.7	0

#	ARTICLE	IF	CITATIONS
805	The effect of acute exercise on circulating immune cells in newly diagnosed breast cancer patients. Scientific Reports, 2023, 13, .	3.3	2
806	Deciphering immune microenvironment and cell evasion mechanisms in human gliomas. Frontiers in Oncology, 0, 13, .	2.8	3
807	A costimulatory chimeric antigen receptor targeting TROP2 enhances the cytotoxicity of NK cells expressing a T cell receptor reactive to human papillomavirus type 16 E7. Cancer Letters, 2023, 566, 216242.	7.2	4
808	Exosome-mediated crosstalk between tumor cells and innate immune cells: implications for cancer progression and therapeutic strategies. Journal of Cancer Research and Clinical Oncology, 2023, 149, 9487-9503.	2.5	4
809	TIGIT Expression on Activated NK Cells Correlates with Greater Anti-Tumor Activity but Promotes Functional Decline upon Lung Cancer Exposure: Implications for Adoptive Cell Therapy and TIGIT-Targeted Therapies. Cancers, 2023, 15, 2712.	3.7	4
810	Current insights into the hepatic microenvironment and advances in immunotherapy for hepatocellular carcinoma. Frontiers in Immunology, 0, 14, .	4.8	6
811	SUMOylation and related post-translational modifications in natural killer cell anti-cancer responses. Frontiers in Cell and Developmental Biology, 0, 11, .	3.7	3
812	Crosstalk of Immune Cells and Platelets in an Ovarian Cancer Microenvironment and Their Prognostic Significance. International Journal of Molecular Sciences, 2023, 24, 9279.	4.1	4
813	Current state-of-the-art on ganglioside-mediated immune modulation in the tumor microenvironment. Cancer and Metastasis Reviews, 2023, 42, 941-958.	5.9	6
814	Catalyst-free thiazolidine formation chemistry enables the facile construction of peptide/proteinâ€cell conjugates (PCCs) at physiological pH. Chemical Science, 2023, 14, 7334-7345.	7.4	3
815	Relationship between Serum Cortisol, Dehydroepiandrosterone Sulfate (DHEAS) Levels, and Natural Killer Cell Activity: A Cross-Sectional Study. Journal of Clinical Medicine, 2023, 12, 4027.	2.4	0
816	Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells. Journal of Hematology and Oncology, 2023, 16, .	17.0	7
817	Role of chemokines in the hepatocellular carcinoma microenvironment and their translational value in immunotherapy*. , 2022, 8, 1-17.		0
818	CAR-NK cell therapy for glioblastoma: what to do next?. Frontiers in Oncology, 0, 13, .	2.8	4
819	Cancer immunotherapy via stem cell-derived NK cells. Immunotherapy, 0, , .	2.0	0
820	Identification and validation of shared genes and key pathways in endometriosis and endometriosisâ€associated ovarian cancer by weighted gene coâ€expression network analysis and machine learning algorithms. Journal of Obstetrics and Gynaecology Research, 2023, 49, 2135-2150.	1.3	0
821	NK cells encapsulated in micro/macropore-forming hydrogels via 3D bioprinting for tumor immunotherapy. Biomaterials Research, 2023, 27, .	6.9	8
822	Roles and implications of mRNA <i>N</i> ⁶ -methyladenosine in cancer. Cancer Communications, 2023, 43, 729-748.	9.2	7

#	ARTICLE	IF	CITATIONS
823	Role of exosomes in the development of the immune microenvironment in hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	4
824	Advances in landscape and related therapeutic targets of the prostate tumor microenvironment. <i>Acta Biochimica Et Biophysica Sinica</i> , 2023, 55, 956-973.	2.0	4
825	Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	17.1	30
826	T cells, NK cells, and tumor-associated macrophages in cancer immunotherapy and the current state of the art of drug delivery systems. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	3
827	Effect of infiltrating immune cells in tumor microenvironment on metastasis of hepatocellular carcinoma. <i>Cellular Oncology (Dordrecht)</i> , 2023, 46, 1595-1604.	4.4	8
828	Prognosis and therapeutic benefits prediction based on NK cell marker genes through single-cell RNA-seq with integrated bulk RNA-seq analysis for hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
829	Natural killer cell therapy targeting cancer stem cells: Old wine in a new bottle. <i>Cancer Letters</i> , 2023, 570, 216328.	7.2	3
830	Natural Killer Cell Activation by Ubiquitin-specific Protease 6 Mediates Tumor Suppression in Ewing Sarcoma. <i>Cancer Research Communications</i> , 2023, 3, 1615-1627.	1.7	0
831	Targeting anticancer immunity in oral cancer: Drugs, products, and nanoparticles. <i>Environmental Research</i> , 2023, 239, 116751.	7.5	5
832	Influenza A Infection Stimulates RIG-I and Enhances Effector Function of Primary Human NK Cells. <i>International Journal of Molecular Sciences</i> , 2023, 24, 12220.	4.1	0
833	Lipid anchor-mediated NK cell surface engineering for enhanced cancer immunotherapy. <i>Chemical Engineering Journal</i> , 2023, 473, 145211.	12.7	7
834	Low Muscle and High Fat Percentages Are Associated with Low Natural Killer Cell Activity: A Cross-Sectional Study. <i>International Journal of Molecular Sciences</i> , 2023, 24, 12505.	4.1	0
835	Memory-like Differentiation, Tumor-Targeting mAbs, and Chimeric Antigen Receptors Enhance Natural Killer Cell Responses to Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 4196-4208.	7.0	1
836	The role of perfluorooctane sulfonic acid (PFOS) exposure in inflammation of intestinal tissues and intestinal carcinogenesis. <i>Frontiers in Toxicology</i> , 0, 5, .	3.1	1
837	NK cells vs. obesity: A tale of dysfunction & redemption. <i>Clinical Immunology</i> , 2023, 255, 109744.	3.2	0
838	Androgen receptor agonist and antagonist reduce response of cytokine-induced killer cells on prostate cancer cells. <i>Journal of Cellular and Molecular Medicine</i> , 0, , .	3.6	0
839	NK Cell-Based Immunotherapy for Malignant Diseases. <i>Advances in Clinical Medicine</i> , 2023, 13, 13836-13842.	0.0	0
840	Methylation across the central dogma in health and diseases: new therapeutic strategies. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	17.1	7

#	ARTICLE	IF	CITATIONS
841	The prospects of microphysiological systems in modeling platelet pathophysiology in cancer. Platelets, 2023, 34, .	2.3	0
842	Adoptive cell therapy in paediatric extracranial solid tumours: current approaches and future challenges. European Journal of Cancer, 2023, 194, 113347.	2.8	0
843	Dysregulation of DNAM-1-Mediated NK Cell Anti-Cancer Responses in the Tumor Microenvironment. Cancers, 2023, 15, 4616.	3.7	0
844	Natural killer cell-derived exosomes for cancer immunotherapy: innovative therapeutics art. Cancer Cell International, 2023, 23, .	4.1	5
845	Exploiting Exosomes for Cancer Diagnosis and Treatment. Current Cancer Research, 2023, , 43-59.	0.2	0
846	The diverse effects of cisplatin on tumor microenvironment: Insights and challenges for the delivery of cisplatin by nanoparticles. Environmental Research, 2024, 240, 117362.	7.5	2
847	Chimeric antigen receptor therapy meets mRNA technology. Trends in Biotechnology, 2024, 42, 228-240.	9.3	1
848	Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer. Frontiers in Immunology, 0, 14, .	4.8	3
849	Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy. Frontiers in Immunology, 0, 14, .	4.8	2
850	Systemic Oncospheres: Host Inflammation and Cancer. , 2023, , 469-495.		0
851	Effects of dexmedetomidine on A549 non-small cell lung cancer growth in a clinically relevant surgical xenograft model. Scientific Reports, 2023, 13, .	3.3	1
852	Harnessing Natural Killer Cells for Lung Cancer Therapy. Cancer Research, 2023, 83, 3327-3339.	0.9	2
853	SLC10A3 Is a Prognostic Biomarker and Involved in Immune Infiltration and Programmed Cell Death in Lower Grade Glioma. World Neurosurgery, 2023, 178, e595-e640.	1.3	0
854	Twelve-week treadmill endurance training in mice is associated with upregulation of interleukin-15 and natural killer cell activation and increases apoptosis rate in Hepa1-6 cell-derived mouse hepatomas. Brazilian Journal of Medical and Biological Research, 0, 56, .	1.5	1
855	Dynamic Changes in miRNA Expression during the Generation of Expanded and Activated NK Cells. International Journal of Molecular Sciences, 2023, 24, 13556.	4.1	0
856	Role of c-Myc in lung cancer: Progress, challenges, and prospects. , 2023, 1, 129-138.		2
857	STING signaling promotes NK cell antitumor immunity and maintains a reservoir of TCF-1+ NK cells. Cell Reports, 2023, 42, 113108.	6.4	3
858	The Immunomodulatory Effect of Various Anaesthetic Practices in Patients Undergoing Gastric or Colon Cancer Surgery: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Journal of Clinical Medicine, 2023, 12, 6027.	2.4	0

#	ARTICLE	IF	CITATIONS
859	Anticancer Drugs at Low Concentrations Upregulate the Activity of Natural Killer Cell. Biomedical Science Letters, 2023, 29, 178-183.	0.3	0
860	Unleashing the Potential of Natural Killer Cells in Immunotherapy for Glioblastoma and Brain Tumors. , 2023, , .		0
861	Identification of SGMS2 as a molecule involved in natural killer cell recruitment and its inâ€deep analysis in the liver cancer microenvironment: Evidence from large populations cohort. Journal of Gene Medicine, 2024, 26, .	2.8	0
862	Unlocking antitumor immunity with adenosine receptor blockers. Cancer Drug Resistance (Alhambra,) Tj ETQq1 1 0,784314 rgBT /Overl	2.1	0
863	Implications of Rectal Cancer Radiotherapy on the Immune Microenvironment: Allies and Foes to Therapy Resistance and Patientsâ€™ Outcome. Cancers, 2023, 15, 5124.	3.7	0
864	Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review). International Journal of Oncology, 2023, 63, .	3.3	0
865	Cell membrane-based biomimetic technology for cancer phototherapy: Mechanisms, recent advances and perspectives. Acta Biomaterialia, 2024, 174, 26-48.	8.3	1
866	Bioactive compounds from Actinidia arguta fruit as a new strategy to fight glioblastoma. Food Research International, 2024, 175, 113770.	6.2	1
867	The impact of liver fibrosis on the progression of hepatocellular carcinoma via a hypoxia-immune-integrated prognostic model. International Immunopharmacology, 2023, 125, 111136.	3.8	1
868	Identification of molecular subtypes and a risk model based on inflammation-related genes in patients with low grade glioma. Heliyon, 2023, 9, e22429.	3.2	0
869	Protein cage nanoparticle-based NK cell-engaging nanodrones (NKeNDs) effectively recruit NK cells to target tumor sites and suppress tumor growth. Nano Today, 2024, 54, 102075.	11.9	0
870	A Nonviral piggyBac Transposon-Mediated Method to Generate Large-Scale CAR-NK Cells from Human Peripheral Blood Primary NK Cells. Methods in Molecular Biology, 2024, , 279-288.	0.9	0
871	Tailoring tumor-recognizable hyaluronic acidâ€lipid conjugates to enhance anticancer efficacies of surface-engineered natural killer cells. Nano Convergence, 2023, 10, .	12.1	2
872	Comparing the Benefits and Drawbacks of Stem Cell Therapy Based on the Cell Origin or Manipulation Process: Addressing Immunogenicity. Immune Network, 2023, 23, .	3.6	0
873	GLIS1, Correlated with Immune Infiltrates, Is a Potential Prognostic Biomarker in Prostate Cancer. International Journal of Molecular Sciences, 2024, 25, 489.	4.1	0
874	Combined use of NK cells and radiotherapy in the treatment of solid tumors. Frontiers in Immunology, 0, 14, .	4.8	0
875	NK cells as powerful therapeutic tool in cancer immunotherapy. Cellular Oncology (Dordrecht), 0, , .	4.4	0
876	Nano-enhanced immunotherapy: Targeting the immunosuppressive tumor microenvironment. Biomaterials, 2024, 305, 122463.	11.4	2

#	ARTICLE	IF	CITATIONS
877	Current drug therapy for colorectal cancer. , 2024, , 115-148.		0
878	Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside. Cell Death and Disease, 2024, 15, .	6.3	0
879	Prognosis and therapy in thyroid cancer by gene signatures related to natural killer cells. Journal of Gene Medicine, 2024, 26, .	2.8	0
880	Sufficiently activated mature natural killer cells derived from peripheral blood mononuclear cells substantially enhance antitumor activity. Immunity, Inflammation and Disease, 2024, 12, .	2.7	0
882	Effective extracellular vesicles in glioma: Focusing on effective ncRNA exosomes and immunotherapy methods for treatment. Cell Biochemistry and Function, 2024, 42, .	2.9	0
883	The role of exhausted natural killer cells in the immunopathogenesis and treatment of leukemia. Cell Communication and Signaling, 2024, 22, .	6.5	0
884	Co-expression of IL-21-Enhanced NKG2D CAR-NK cell therapy for lung cancer. BMC Cancer, 2024, 24, .	2.6	1
885	A promising natural killer cell-based model and a nomogram for the prognostic prediction of clear-cell renal cell carcinoma. European Journal of Medical Research, 2024, 29, .	2.2	0
886	Reprogramming natural killer cells for cancer therapy. Molecular Therapy, 2024, , .	8.2	0
887	Evidence and therapeutic implications of biomechanically regulated immunosurveillance in cancer and other diseases. Nature Nanotechnology, 2024, 19, 281-297.	31.5	0
889	Donor Age Correlates With Liver-Resident Natural Killer Cell Activity in Adoptive Immunotherapy Using Donor Liver Natural Killer Cells in Liver Transplantation. Transplantation Proceedings, 2024, 56, 667-671.	0.6	0
890	SOCS1 expression in cancer cells: potential roles in promoting antitumor immunity. Frontiers in Immunology, 0, 15, .	4.8	0
891	Glioblastoma Therapy: Past, Present and Future. International Journal of Molecular Sciences, 2024, 25, 2529.	4.1	0
892	Immunity from NK Cell Subsets Is Important for Vaccine-Mediated Protection in HPV+ Cancers. Vaccines, 2024, 12, 206.	4.4	0
893	Natural killer cell therapies. Nature, 2024, 626, 727-736.	27.8	0
894	Different evasion strategies in multiple myeloma. Frontiers in Immunology, 0, 15, .	4.8	0
895	CAR-NK cells in combination therapy against cancer: A potential paradigm. Heliyon, 2024, 10, e27196.	3.2	0
896	Results of a phase I trial with Haploidentical <sc>mbIL</sc>â€²1 ex vivo expanded <sc>NK</sc> cells for patients with multiply relapsed and refractory <sc>AML</sc>. American Journal of Hematology, 2024, 99, 890-899.	4.1	0

#	ARTICLE	IF	CITATIONS
897	Physical activity and exercise in liver cancer. Liver Research, 2024, 8, 22-33.	1.4	0
898	Targeting YAP1 to improve the efficacy of immune checkpoint inhibitors in liver cancer: mechanism and strategy. Frontiers in Immunology, 0, 15, .	4.8	0
899	Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice. , 2024, 12, e008295.		0
900	A single bout of vigorous intensity exercise enhances the efficacy of rituximab against human chronic lymphocytic leukaemia B-cells ex vivo. Brain, Behavior, and Immunity, 2024, 118, 468-479.	4.1	0
901	Prognostic Signature in Osteosarcoma Based on Amino Acid Metabolism-Associated Genes. Cancer Biotherapy and Radiopharmaceuticals, 0, , .	1.0	0
902	Pediatric Solid Cancers: Dissecting the Tumor Microenvironment to Improve the Results of Clinical Immunotherapy. International Journal of Molecular Sciences, 2024, 25, 3225.	4.1	0
903	Immune modulation in malignant pleural effusion: from microenvironment to therapeutic implications. Cancer Cell International, 2024, 24, .	4.1	0